Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
Identifieur interne : 000310 ( Pmc/Corpus ); précédent : 000309; suivant : 000311Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
Auteurs : George K. Bertsias ; Maria Tektonidou ; Zahir Amoura ; Martin Aringer ; Ingeborg Bajema ; Jo H M. Berden ; John Boletis ; Ricard Cervera ; Thomas Dörner ; Andrea Doria ; Franco Ferrario ; Jürgen Floege ; Frederic A. Houssiau ; John P A. Ioannidis ; David A. Isenberg ; Cees G M. Kallenberg ; Liz Lightstone ; Stephen D. Marks ; Alberto Martini ; Gabriela Moroni ; Irmgard Neumann ; Manuel Praga ; Matthias Schneider ; Argyre Starra ; Vladimir Tesar ; Carlos Vasconcelos ; Ronald F. Van Vollenhoven ; Helena Zakharova ; Marion Haubitz ; Caroline Gordon ; David Jayne ; Dimitrios T. BoumpasSource :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2012.
Abstract
To develop recommendations for the management of adult and paediatric lupus nephritis (LN).
The available evidence was systematically reviewed using the PubMed database. A modified Delphi method was used to compile questions, elicit expert opinions and reach consensus.
Immunosuppressive treatment should be guided by renal biopsy, and aiming for complete renal response (proteinuria <0.5 g/24 h with normal or near-normal renal function). Hydroxychloroquine is recommended for all patients with LN. Because of a more favourable efficacy/toxicity ratio, as initial treatment for patients with class III–IVA or A/C (±V) LN according to the International Society of Nephrology/Renal Pathology Society 2003 classification, mycophenolic acid (MPA) or low-dose intravenous cyclophosphamide (CY) in combination with glucocorticoids is recommended. In patients with adverse clinical or histological features, CY can be prescribed at higher doses, while azathioprine is an alternative for milder cases. For pure class V LN with nephrotic-range proteinuria, MPA in combination with oral glucocorticoids is recommended as initial treatment. In patients improving after initial treatment, subsequent immunosuppression with MPA or azathioprine is recommended for at least 3 years; in such cases, initial treatment with MPA should be followed by MPA. For MPA or CY failures, switching to the other agent, or to rituximab, is the suggested course of action. In anticipation of pregnancy, patients should be switched to appropriate medications without reducing the intensity of treatment. There is no evidence to suggest that management of LN should differ in children versus adults.
Recommendations for the management of LN were developed using an evidence-based approach followed by expert consensus.
Url:
DOI: 10.1136/annrheumdis-2012-201940
PubMed: 22851469
PubMed Central: 3465859
Links to Exploration step
PMC:3465859Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis</title><author><name sortKey="Bertsias, George K" sort="Bertsias, George K" uniqKey="Bertsias G" first="George K" last="Bertsias">George K. Bertsias</name><affiliation><nlm:aff id="af1">Department of Medicine, Rheumatology, Clinical Immunology and Allergy, University of Crete, Iraklion, Greece</nlm:aff></affiliation></author><author><name sortKey="Tektonidou, Maria" sort="Tektonidou, Maria" uniqKey="Tektonidou M" first="Maria" last="Tektonidou">Maria Tektonidou</name><affiliation><nlm:aff id="af2">First Department of Internal Medicine, Rheumatology, University of Athens, Athens, Greece</nlm:aff></affiliation></author><author><name sortKey="Amoura, Zahir" sort="Amoura, Zahir" uniqKey="Amoura Z" first="Zahir" last="Amoura">Zahir Amoura</name><affiliation><nlm:aff id="af3">Department of Internal Medicine, French National Reference Center for SLE, Université Paris VI Pierre et Marie Curie, Hôpital Pitié-Salpêtrière, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Aringer, Martin" sort="Aringer, Martin" uniqKey="Aringer M" first="Martin" last="Aringer">Martin Aringer</name><affiliation><nlm:aff id="af4">Division of Rheumatology, Department of Medicine III, University Medical Center Carl Gustav Carus, Dresden, Germany</nlm:aff></affiliation></author><author><name sortKey="Bajema, Ingeborg" sort="Bajema, Ingeborg" uniqKey="Bajema I" first="Ingeborg" last="Bajema">Ingeborg Bajema</name><affiliation><nlm:aff id="af5">Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands</nlm:aff></affiliation></author><author><name sortKey="Berden, Jo H M" sort="Berden, Jo H M" uniqKey="Berden J" first="Jo H M" last="Berden">Jo H M. Berden</name><affiliation><nlm:aff id="af6">Department of Nephrology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands</nlm:aff></affiliation></author><author><name sortKey="Boletis, John" sort="Boletis, John" uniqKey="Boletis J" first="John" last="Boletis">John Boletis</name><affiliation><nlm:aff id="af7">Department of Nephrology and Transplantation Center, Laiko General Hospital, Athens, Greece</nlm:aff></affiliation></author><author><name sortKey="Cervera, Ricard" sort="Cervera, Ricard" uniqKey="Cervera R" first="Ricard" last="Cervera">Ricard Cervera</name><affiliation><nlm:aff id="af8">Department of Autoimmune Diseases, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Dorner, Thomas" sort="Dorner, Thomas" uniqKey="Dorner T" first="Thomas" last="Dörner">Thomas Dörner</name><affiliation><nlm:aff id="af9">Department of Medicine, Rheumatology and Clinical Immunology, Charité—University Medicine Berlin, Berlin, Germany</nlm:aff></affiliation></author><author><name sortKey="Doria, Andrea" sort="Doria, Andrea" uniqKey="Doria A" first="Andrea" last="Doria">Andrea Doria</name><affiliation><nlm:aff id="af10">Division of Rheumatology, Department of Medicine, University of Padova, Padova, Italy</nlm:aff></affiliation></author><author><name sortKey="Ferrario, Franco" sort="Ferrario, Franco" uniqKey="Ferrario F" first="Franco" last="Ferrario">Franco Ferrario</name><affiliation><nlm:aff id="af11">Nephropathology Center, San Gerardo Hospital, Monza and Milan Bicocca University, Monza, Italy</nlm:aff></affiliation></author><author><name sortKey="Floege, Jurgen" sort="Floege, Jurgen" uniqKey="Floege J" first="Jürgen" last="Floege">Jürgen Floege</name><affiliation><nlm:aff id="af12">Division of Nephrology and Clinical Immunology, RWTH University of Aachen, Aachen, Germany</nlm:aff></affiliation></author><author><name sortKey="Houssiau, Frederic A" sort="Houssiau, Frederic A" uniqKey="Houssiau F" first="Frederic A" last="Houssiau">Frederic A. Houssiau</name><affiliation><nlm:aff id="af13">Department of Rheumatology, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Bruxelles, Belgium</nlm:aff></affiliation></author><author><name sortKey="Ioannidis, John P A" sort="Ioannidis, John P A" uniqKey="Ioannidis J" first="John P A" last="Ioannidis">John P A. Ioannidis</name><affiliation><nlm:aff id="af14">Stanford Prevention Research Center, Department of Medicine, and Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California, USA</nlm:aff></affiliation></author><author><name sortKey="Isenberg, David A" sort="Isenberg, David A" uniqKey="Isenberg D" first="David A" last="Isenberg">David A. Isenberg</name><affiliation><nlm:aff id="af15">Centre for Rheumatology Research, Division of Medicine, University College London, London, UK</nlm:aff></affiliation></author><author><name sortKey="Kallenberg, Cees G M" sort="Kallenberg, Cees G M" uniqKey="Kallenberg C" first="Cees G M" last="Kallenberg">Cees G M. Kallenberg</name><affiliation><nlm:aff id="af16">Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands</nlm:aff></affiliation></author><author><name sortKey="Lightstone, Liz" sort="Lightstone, Liz" uniqKey="Lightstone L" first="Liz" last="Lightstone">Liz Lightstone</name><affiliation><nlm:aff id="af17">Section of Renal Medicine, Division of Immunology and Inflammation, Department of Medicine, Imperial College London, London, UK</nlm:aff></affiliation></author><author><name sortKey="Marks, Stephen D" sort="Marks, Stephen D" uniqKey="Marks S" first="Stephen D" last="Marks">Stephen D. Marks</name><affiliation><nlm:aff id="af18">Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Trust, London, UK</nlm:aff></affiliation></author><author><name sortKey="Martini, Alberto" sort="Martini, Alberto" uniqKey="Martini A" first="Alberto" last="Martini">Alberto Martini</name><affiliation><nlm:aff id="af19">Pediatria II, Reumatologia, IRCCS Istituto G Gaslini, Università di Genova, Genova, Italy</nlm:aff></affiliation></author><author><name sortKey="Moroni, Gabriela" sort="Moroni, Gabriela" uniqKey="Moroni G" first="Gabriela" last="Moroni">Gabriela Moroni</name><affiliation><nlm:aff id="af20">Divisione di Nefrologia e Dialisi Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Neumann, Irmgard" sort="Neumann, Irmgard" uniqKey="Neumann I" first="Irmgard" last="Neumann">Irmgard Neumann</name><affiliation><nlm:aff id="af21">Division of Nephrology, Internal Medicine, Wilhelminenspital, Vienna, Austria</nlm:aff></affiliation></author><author><name sortKey="Praga, Manuel" sort="Praga, Manuel" uniqKey="Praga M" first="Manuel" last="Praga">Manuel Praga</name><affiliation><nlm:aff id="af22">Nephrology Division, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain</nlm:aff></affiliation></author><author><name sortKey="Schneider, Matthias" sort="Schneider, Matthias" uniqKey="Schneider M" first="Matthias" last="Schneider">Matthias Schneider</name><affiliation><nlm:aff id="af23">Department of Medicine, Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany</nlm:aff></affiliation></author><author><name sortKey="Starra, Argyre" sort="Starra, Argyre" uniqKey="Starra A" first="Argyre" last="Starra">Argyre Starra</name><affiliation><nlm:aff id="af24"><italic>Patient representative</italic> (Iraklio), Rethymnon, Greece</nlm:aff></affiliation></author><author><name sortKey="Tesar, Vladimir" sort="Tesar, Vladimir" uniqKey="Tesar V" first="Vladimir" last="Tesar">Vladimir Tesar</name><affiliation><nlm:aff id="af25">Department of Nephrology, First School of Medicine, Charles University, Prague, Czech Republic</nlm:aff></affiliation></author><author><name sortKey="Vasconcelos, Carlos" sort="Vasconcelos, Carlos" uniqKey="Vasconcelos C" first="Carlos" last="Vasconcelos">Carlos Vasconcelos</name><affiliation><nlm:aff id="af26">Unidade de Imunologia Clinica, Hospital Santo Antonio, Centro Hospitalar do Porto, UMIB-ICBAS, Universidade do Porto, Porto, Portugal</nlm:aff></affiliation></author><author><name sortKey="Van Vollenhoven, Ronald F" sort="Van Vollenhoven, Ronald F" uniqKey="Van Vollenhoven R" first="Ronald F" last="Van Vollenhoven">Ronald F. Van Vollenhoven</name><affiliation><nlm:aff id="af27">Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Stockholm, Sweden</nlm:aff></affiliation></author><author><name sortKey="Zakharova, Helena" sort="Zakharova, Helena" uniqKey="Zakharova H" first="Helena" last="Zakharova">Helena Zakharova</name><affiliation><nlm:aff id="af28">Nephrology Unit, Moscow City Hospital n.a. S.P. Botkin, Moscow State Medicine and Dentistry University, Moscow, Russian Federation</nlm:aff></affiliation></author><author><name sortKey="Haubitz, Marion" sort="Haubitz, Marion" uniqKey="Haubitz M" first="Marion" last="Haubitz">Marion Haubitz</name><affiliation><nlm:aff id="af29">Department of Nephrology and Hypertension, Hannover Medical School, Hannover and Klinikum Fulda, Fulda, Germany</nlm:aff></affiliation></author><author><name sortKey="Gordon, Caroline" sort="Gordon, Caroline" uniqKey="Gordon C" first="Caroline" last="Gordon">Caroline Gordon</name><affiliation><nlm:aff id="af30">Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, West Midlands, UK</nlm:aff></affiliation></author><author><name sortKey="Jayne, David" sort="Jayne, David" uniqKey="Jayne D" first="David" last="Jayne">David Jayne</name><affiliation><nlm:aff id="af31">Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK</nlm:aff></affiliation></author><author><name sortKey="Boumpas, Dimitrios T" sort="Boumpas, Dimitrios T" uniqKey="Boumpas D" first="Dimitrios T" last="Boumpas">Dimitrios T. Boumpas</name><affiliation><nlm:aff id="af1">Department of Medicine, Rheumatology, Clinical Immunology and Allergy, University of Crete, Iraklion, Greece</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22851469</idno><idno type="pmc">3465859</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465859</idno><idno type="RBID">PMC:3465859</idno><idno type="doi">10.1136/annrheumdis-2012-201940</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">000310</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis</title><author><name sortKey="Bertsias, George K" sort="Bertsias, George K" uniqKey="Bertsias G" first="George K" last="Bertsias">George K. Bertsias</name><affiliation><nlm:aff id="af1">Department of Medicine, Rheumatology, Clinical Immunology and Allergy, University of Crete, Iraklion, Greece</nlm:aff></affiliation></author><author><name sortKey="Tektonidou, Maria" sort="Tektonidou, Maria" uniqKey="Tektonidou M" first="Maria" last="Tektonidou">Maria Tektonidou</name><affiliation><nlm:aff id="af2">First Department of Internal Medicine, Rheumatology, University of Athens, Athens, Greece</nlm:aff></affiliation></author><author><name sortKey="Amoura, Zahir" sort="Amoura, Zahir" uniqKey="Amoura Z" first="Zahir" last="Amoura">Zahir Amoura</name><affiliation><nlm:aff id="af3">Department of Internal Medicine, French National Reference Center for SLE, Université Paris VI Pierre et Marie Curie, Hôpital Pitié-Salpêtrière, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Aringer, Martin" sort="Aringer, Martin" uniqKey="Aringer M" first="Martin" last="Aringer">Martin Aringer</name><affiliation><nlm:aff id="af4">Division of Rheumatology, Department of Medicine III, University Medical Center Carl Gustav Carus, Dresden, Germany</nlm:aff></affiliation></author><author><name sortKey="Bajema, Ingeborg" sort="Bajema, Ingeborg" uniqKey="Bajema I" first="Ingeborg" last="Bajema">Ingeborg Bajema</name><affiliation><nlm:aff id="af5">Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands</nlm:aff></affiliation></author><author><name sortKey="Berden, Jo H M" sort="Berden, Jo H M" uniqKey="Berden J" first="Jo H M" last="Berden">Jo H M. Berden</name><affiliation><nlm:aff id="af6">Department of Nephrology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands</nlm:aff></affiliation></author><author><name sortKey="Boletis, John" sort="Boletis, John" uniqKey="Boletis J" first="John" last="Boletis">John Boletis</name><affiliation><nlm:aff id="af7">Department of Nephrology and Transplantation Center, Laiko General Hospital, Athens, Greece</nlm:aff></affiliation></author><author><name sortKey="Cervera, Ricard" sort="Cervera, Ricard" uniqKey="Cervera R" first="Ricard" last="Cervera">Ricard Cervera</name><affiliation><nlm:aff id="af8">Department of Autoimmune Diseases, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Dorner, Thomas" sort="Dorner, Thomas" uniqKey="Dorner T" first="Thomas" last="Dörner">Thomas Dörner</name><affiliation><nlm:aff id="af9">Department of Medicine, Rheumatology and Clinical Immunology, Charité—University Medicine Berlin, Berlin, Germany</nlm:aff></affiliation></author><author><name sortKey="Doria, Andrea" sort="Doria, Andrea" uniqKey="Doria A" first="Andrea" last="Doria">Andrea Doria</name><affiliation><nlm:aff id="af10">Division of Rheumatology, Department of Medicine, University of Padova, Padova, Italy</nlm:aff></affiliation></author><author><name sortKey="Ferrario, Franco" sort="Ferrario, Franco" uniqKey="Ferrario F" first="Franco" last="Ferrario">Franco Ferrario</name><affiliation><nlm:aff id="af11">Nephropathology Center, San Gerardo Hospital, Monza and Milan Bicocca University, Monza, Italy</nlm:aff></affiliation></author><author><name sortKey="Floege, Jurgen" sort="Floege, Jurgen" uniqKey="Floege J" first="Jürgen" last="Floege">Jürgen Floege</name><affiliation><nlm:aff id="af12">Division of Nephrology and Clinical Immunology, RWTH University of Aachen, Aachen, Germany</nlm:aff></affiliation></author><author><name sortKey="Houssiau, Frederic A" sort="Houssiau, Frederic A" uniqKey="Houssiau F" first="Frederic A" last="Houssiau">Frederic A. Houssiau</name><affiliation><nlm:aff id="af13">Department of Rheumatology, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Bruxelles, Belgium</nlm:aff></affiliation></author><author><name sortKey="Ioannidis, John P A" sort="Ioannidis, John P A" uniqKey="Ioannidis J" first="John P A" last="Ioannidis">John P A. Ioannidis</name><affiliation><nlm:aff id="af14">Stanford Prevention Research Center, Department of Medicine, and Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California, USA</nlm:aff></affiliation></author><author><name sortKey="Isenberg, David A" sort="Isenberg, David A" uniqKey="Isenberg D" first="David A" last="Isenberg">David A. Isenberg</name><affiliation><nlm:aff id="af15">Centre for Rheumatology Research, Division of Medicine, University College London, London, UK</nlm:aff></affiliation></author><author><name sortKey="Kallenberg, Cees G M" sort="Kallenberg, Cees G M" uniqKey="Kallenberg C" first="Cees G M" last="Kallenberg">Cees G M. Kallenberg</name><affiliation><nlm:aff id="af16">Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands</nlm:aff></affiliation></author><author><name sortKey="Lightstone, Liz" sort="Lightstone, Liz" uniqKey="Lightstone L" first="Liz" last="Lightstone">Liz Lightstone</name><affiliation><nlm:aff id="af17">Section of Renal Medicine, Division of Immunology and Inflammation, Department of Medicine, Imperial College London, London, UK</nlm:aff></affiliation></author><author><name sortKey="Marks, Stephen D" sort="Marks, Stephen D" uniqKey="Marks S" first="Stephen D" last="Marks">Stephen D. Marks</name><affiliation><nlm:aff id="af18">Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Trust, London, UK</nlm:aff></affiliation></author><author><name sortKey="Martini, Alberto" sort="Martini, Alberto" uniqKey="Martini A" first="Alberto" last="Martini">Alberto Martini</name><affiliation><nlm:aff id="af19">Pediatria II, Reumatologia, IRCCS Istituto G Gaslini, Università di Genova, Genova, Italy</nlm:aff></affiliation></author><author><name sortKey="Moroni, Gabriela" sort="Moroni, Gabriela" uniqKey="Moroni G" first="Gabriela" last="Moroni">Gabriela Moroni</name><affiliation><nlm:aff id="af20">Divisione di Nefrologia e Dialisi Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Neumann, Irmgard" sort="Neumann, Irmgard" uniqKey="Neumann I" first="Irmgard" last="Neumann">Irmgard Neumann</name><affiliation><nlm:aff id="af21">Division of Nephrology, Internal Medicine, Wilhelminenspital, Vienna, Austria</nlm:aff></affiliation></author><author><name sortKey="Praga, Manuel" sort="Praga, Manuel" uniqKey="Praga M" first="Manuel" last="Praga">Manuel Praga</name><affiliation><nlm:aff id="af22">Nephrology Division, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain</nlm:aff></affiliation></author><author><name sortKey="Schneider, Matthias" sort="Schneider, Matthias" uniqKey="Schneider M" first="Matthias" last="Schneider">Matthias Schneider</name><affiliation><nlm:aff id="af23">Department of Medicine, Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany</nlm:aff></affiliation></author><author><name sortKey="Starra, Argyre" sort="Starra, Argyre" uniqKey="Starra A" first="Argyre" last="Starra">Argyre Starra</name><affiliation><nlm:aff id="af24"><italic>Patient representative</italic> (Iraklio), Rethymnon, Greece</nlm:aff></affiliation></author><author><name sortKey="Tesar, Vladimir" sort="Tesar, Vladimir" uniqKey="Tesar V" first="Vladimir" last="Tesar">Vladimir Tesar</name><affiliation><nlm:aff id="af25">Department of Nephrology, First School of Medicine, Charles University, Prague, Czech Republic</nlm:aff></affiliation></author><author><name sortKey="Vasconcelos, Carlos" sort="Vasconcelos, Carlos" uniqKey="Vasconcelos C" first="Carlos" last="Vasconcelos">Carlos Vasconcelos</name><affiliation><nlm:aff id="af26">Unidade de Imunologia Clinica, Hospital Santo Antonio, Centro Hospitalar do Porto, UMIB-ICBAS, Universidade do Porto, Porto, Portugal</nlm:aff></affiliation></author><author><name sortKey="Van Vollenhoven, Ronald F" sort="Van Vollenhoven, Ronald F" uniqKey="Van Vollenhoven R" first="Ronald F" last="Van Vollenhoven">Ronald F. Van Vollenhoven</name><affiliation><nlm:aff id="af27">Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Stockholm, Sweden</nlm:aff></affiliation></author><author><name sortKey="Zakharova, Helena" sort="Zakharova, Helena" uniqKey="Zakharova H" first="Helena" last="Zakharova">Helena Zakharova</name><affiliation><nlm:aff id="af28">Nephrology Unit, Moscow City Hospital n.a. S.P. Botkin, Moscow State Medicine and Dentistry University, Moscow, Russian Federation</nlm:aff></affiliation></author><author><name sortKey="Haubitz, Marion" sort="Haubitz, Marion" uniqKey="Haubitz M" first="Marion" last="Haubitz">Marion Haubitz</name><affiliation><nlm:aff id="af29">Department of Nephrology and Hypertension, Hannover Medical School, Hannover and Klinikum Fulda, Fulda, Germany</nlm:aff></affiliation></author><author><name sortKey="Gordon, Caroline" sort="Gordon, Caroline" uniqKey="Gordon C" first="Caroline" last="Gordon">Caroline Gordon</name><affiliation><nlm:aff id="af30">Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, West Midlands, UK</nlm:aff></affiliation></author><author><name sortKey="Jayne, David" sort="Jayne, David" uniqKey="Jayne D" first="David" last="Jayne">David Jayne</name><affiliation><nlm:aff id="af31">Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK</nlm:aff></affiliation></author><author><name sortKey="Boumpas, Dimitrios T" sort="Boumpas, Dimitrios T" uniqKey="Boumpas D" first="Dimitrios T" last="Boumpas">Dimitrios T. Boumpas</name><affiliation><nlm:aff id="af1">Department of Medicine, Rheumatology, Clinical Immunology and Allergy, University of Crete, Iraklion, Greece</nlm:aff></affiliation></author></analytic><series><title level="j">Annals of the Rheumatic Diseases</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Objectives</title><p>To develop recommendations for the management of adult and paediatric lupus nephritis (LN).</p></sec><sec><title>Methods</title><p>The available evidence was systematically reviewed using the PubMed database. A modified Delphi method was used to compile questions, elicit expert opinions and reach consensus.</p></sec><sec><title>Results</title><p>Immunosuppressive treatment should be guided by renal biopsy, and aiming for complete renal response (proteinuria <0.5 g/24 h with normal or near-normal renal function). Hydroxychloroquine is recommended for all patients with LN. Because of a more favourable efficacy/toxicity ratio, as initial treatment for patients with class III–IV<sub>A</sub> or <sub>A/C</sub> (±V) LN according to the International Society of Nephrology/Renal Pathology Society 2003 classification, mycophenolic acid (MPA) or low-dose intravenous cyclophosphamide (CY) in combination with glucocorticoids is recommended. In patients with adverse clinical or histological features, CY can be prescribed at higher doses, while azathioprine is an alternative for milder cases. For pure class V LN with nephrotic-range proteinuria, MPA in combination with oral glucocorticoids is recommended as initial treatment. In patients improving after initial treatment, subsequent immunosuppression with MPA or azathioprine is recommended for at least 3 years; in such cases, initial treatment with MPA should be followed by MPA. For MPA or CY failures, switching to the other agent, or to rituximab, is the suggested course of action. In anticipation of pregnancy, patients should be switched to appropriate medications without reducing the intensity of treatment. There is no evidence to suggest that management of LN should differ in children versus adults.</p></sec><sec><title>Conclusions</title><p>Recommendations for the management of LN were developed using an evidence-based approach followed by expert consensus.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Bertsias, G" uniqKey="Bertsias G">G Bertsias</name></author><author><name sortKey="Ioannidis, Jp" uniqKey="Ioannidis J">JP Ioannidis</name></author><author><name sortKey="Boletis, J" uniqKey="Boletis J">J Boletis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dougados, M" uniqKey="Dougados M">M Dougados</name></author><author><name sortKey="Betteridge, N" uniqKey="Betteridge N">N Betteridge</name></author><author><name sortKey="Burmester, Gr" uniqKey="Burmester G">GR Burmester</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Appenzeller, S" uniqKey="Appenzeller S">S Appenzeller</name></author><author><name sortKey="Clark, A" uniqKey="Clark A">A Clark</name></author><author><name sortKey="Pineau, C" uniqKey="Pineau C">C Pineau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rahman, P" uniqKey="Rahman P">P Rahman</name></author><author><name sortKey="Gladman, Dd" uniqKey="Gladman D">DD Gladman</name></author><author><name sortKey="Ibanez, D" uniqKey="Ibanez D">D Ibanez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leaker, B" uniqKey="Leaker B">B Leaker</name></author><author><name sortKey="Fairley, Kf" uniqKey="Fairley K">KF Fairley</name></author><author><name sortKey="Dowling, J" uniqKey="Dowling J">J Dowling</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nossent, Hc" uniqKey="Nossent H">HC Nossent</name></author><author><name sortKey="Henzen Logmans, Sc" uniqKey="Henzen Logmans S">SC Henzen-Logmans</name></author><author><name sortKey="Vroom, Tm" uniqKey="Vroom T">TM Vroom</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tisseverasinghe, A" uniqKey="Tisseverasinghe A">A Tisseverasinghe</name></author><author><name sortKey="Lim, S" uniqKey="Lim S">S Lim</name></author><author><name sortKey="Greenwood, C" uniqKey="Greenwood C">C Greenwood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grootscholten, C" uniqKey="Grootscholten C">C Grootscholten</name></author><author><name sortKey="Bajema, Im" uniqKey="Bajema I">IM Bajema</name></author><author><name sortKey="Florquin, S" uniqKey="Florquin S">S Florquin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reich, Hn" uniqKey="Reich H">HN Reich</name></author><author><name sortKey="Gladman, Dd" uniqKey="Gladman D">DD Gladman</name></author><author><name sortKey="Urowitz, Mb" uniqKey="Urowitz M">MB Urowitz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kasitanon, N" uniqKey="Kasitanon N">N Kasitanon</name></author><author><name sortKey="Fine, Dm" uniqKey="Fine D">DM Fine</name></author><author><name sortKey="Haas, M" uniqKey="Haas M">M Haas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Petri, M" uniqKey="Petri M">M Petri</name></author><author><name sortKey="Bockenstedt, L" uniqKey="Bockenstedt L">L Bockenstedt</name></author><author><name sortKey="Colman, J" uniqKey="Colman J">J Colman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Esdaile, Jm" uniqKey="Esdaile J">JM Esdaile</name></author><author><name sortKey="Levinton, C" uniqKey="Levinton C">C Levinton</name></author><author><name sortKey="Federgreen, W" uniqKey="Federgreen W">W Federgreen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moroni, G" uniqKey="Moroni G">G Moroni</name></author><author><name sortKey="Gallelli, B" uniqKey="Gallelli B">B Gallelli</name></author><author><name sortKey="Quaglini, S" uniqKey="Quaglini S">S Quaglini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Faurschou, M" uniqKey="Faurschou M">M Faurschou</name></author><author><name sortKey="Starklint, H" uniqKey="Starklint H">H Starklint</name></author><author><name sortKey="Halberg, P" uniqKey="Halberg P">P Halberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weening, Jj" uniqKey="Weening J">JJ Weening</name></author><author><name sortKey="D Agati, Vd" uniqKey="D Agati V">VD D'Agati</name></author><author><name sortKey="Schwartz, Mm" uniqKey="Schwartz M">MM Schwartz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Furness, Pn" uniqKey="Furness P">PN Furness</name></author><author><name sortKey="Taub, N" uniqKey="Taub N">N Taub</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grootscholten, C" uniqKey="Grootscholten C">C Grootscholten</name></author><author><name sortKey="Bajema, Im" uniqKey="Bajema I">IM Bajema</name></author><author><name sortKey="Florquin, S" uniqKey="Florquin S">S Florquin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="O Dell, Jr" uniqKey="O Dell J">JR O'Dell</name></author><author><name sortKey="Hays, Rc" uniqKey="Hays R">RC Hays</name></author><author><name sortKey="Guggenheim, Sj" uniqKey="Guggenheim S">SJ Guggenheim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Esdaile, Jm" uniqKey="Esdaile J">JM Esdaile</name></author><author><name sortKey="Federgreen, W" uniqKey="Federgreen W">W Federgreen</name></author><author><name sortKey="Quintal, H" uniqKey="Quintal H">H Quintal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Austin, Ha" uniqKey="Austin H">HA Austin</name></author><author><name sortKey="Boumpas, Dt" uniqKey="Boumpas D">DT Boumpas</name></author><author><name sortKey="Vaughan, Em" uniqKey="Vaughan E">EM Vaughan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hill, Gs" uniqKey="Hill G">GS Hill</name></author><author><name sortKey="Delahousse, M" uniqKey="Delahousse M">M Delahousse</name></author><author><name sortKey="Nochy, D" uniqKey="Nochy D">D Nochy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ogawa, H" uniqKey="Ogawa H">H Ogawa</name></author><author><name sortKey="Kameda, H" uniqKey="Kameda H">H Kameda</name></author><author><name sortKey="Nagasawa, H" uniqKey="Nagasawa H">H Nagasawa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Descombes, E" uniqKey="Descombes E">E Descombes</name></author><author><name sortKey="Droz, D" uniqKey="Droz D">D Droz</name></author><author><name sortKey="Drouet, L" uniqKey="Drouet L">L Drouet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Corwin, Hl" uniqKey="Corwin H">HL Corwin</name></author><author><name sortKey="Schwartz, Mm" uniqKey="Schwartz M">MM Schwartz</name></author><author><name sortKey="Lewis, Ej" uniqKey="Lewis E">EJ Lewis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Magil, Ab" uniqKey="Magil A">AB Magil</name></author><author><name sortKey="Ballon, Hs" uniqKey="Ballon H">HS Ballon</name></author><author><name sortKey="Chan, V" uniqKey="Chan V">V Chan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nossent, H" uniqKey="Nossent H">H Nossent</name></author><author><name sortKey="Berden, J" uniqKey="Berden J">J Berden</name></author><author><name sortKey="Swaak, T" uniqKey="Swaak T">T Swaak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Austin, Ha" uniqKey="Austin H">HA Austin</name></author><author><name sortKey="Muenz, Lr" uniqKey="Muenz L">LR Muenz</name></author><author><name sortKey="Joyce, Km" uniqKey="Joyce K">KM Joyce</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Whiting O Keefe, Q" uniqKey="Whiting O Keefe Q">Q Whiting-O'Keefe</name></author><author><name sortKey="Henke, Je" uniqKey="Henke J">JE Henke</name></author><author><name sortKey="Shearn, Ma" uniqKey="Shearn M">MA Shearn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Whiting O Keefe, Q" uniqKey="Whiting O Keefe Q">Q Whiting-O'Keefe</name></author><author><name sortKey="Riccardi, Pj" uniqKey="Riccardi P">PJ Riccardi</name></author><author><name sortKey="Henke, Je" uniqKey="Henke J">JE Henke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Faurschou, M" uniqKey="Faurschou M">M Faurschou</name></author><author><name sortKey="Dreyer, L" uniqKey="Dreyer L">L Dreyer</name></author><author><name sortKey="Kamper, Al" uniqKey="Kamper A">AL Kamper</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mok, Cc" uniqKey="Mok C">CC Mok</name></author><author><name sortKey="Cheung, Tt" uniqKey="Cheung T">TT Cheung</name></author><author><name sortKey="Lo, Wh" uniqKey="Lo W">WH Lo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hiramatsu, N" uniqKey="Hiramatsu N">N Hiramatsu</name></author><author><name sortKey="Kuroiwa, T" uniqKey="Kuroiwa T">T Kuroiwa</name></author><author><name sortKey="Ikeuchi, H" uniqKey="Ikeuchi H">H Ikeuchi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Houssiau, Fa" uniqKey="Houssiau F">FA Houssiau</name></author><author><name sortKey="Vasconcelos, C" uniqKey="Vasconcelos C">C Vasconcelos</name></author><author><name sortKey="D Cruz, D" uniqKey="D Cruz D">D D'Cruz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Illei, Gg" uniqKey="Illei G">GG Illei</name></author><author><name sortKey="Takada, K" uniqKey="Takada K">K Takada</name></author><author><name sortKey="Parkin, D" uniqKey="Parkin D">D Parkin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mok, Cc" uniqKey="Mok C">CC Mok</name></author><author><name sortKey="Ying, Ky" uniqKey="Ying K">KY Ying</name></author><author><name sortKey="Ng, Wl" uniqKey="Ng W">WL Ng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, Ye" uniqKey="Chen Y">YE Chen</name></author><author><name sortKey="Korbet, Sm" uniqKey="Korbet S">SM Korbet</name></author><author><name sortKey="Katz, Rs" uniqKey="Katz R">RS Katz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mok, Cc" uniqKey="Mok C">CC Mok</name></author><author><name sortKey="Ying, Ky" uniqKey="Ying K">KY Ying</name></author><author><name sortKey="Tang, S" uniqKey="Tang S">S Tang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moroni, G" uniqKey="Moroni G">G Moroni</name></author><author><name sortKey="Quaglini, S" uniqKey="Quaglini S">S Quaglini</name></author><author><name sortKey="Maccario, M" uniqKey="Maccario M">M Maccario</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moroni, G" uniqKey="Moroni G">G Moroni</name></author><author><name sortKey="Quaglini, S" uniqKey="Quaglini S">S Quaglini</name></author><author><name sortKey="Gallelli, B" uniqKey="Gallelli B">B Gallelli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ward, Mm" uniqKey="Ward M">MM Ward</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Austin, Ha" uniqKey="Austin H">HA Austin</name></author><author><name sortKey="Klippel, Jh" uniqKey="Klippel J">JH Klippel</name></author><author><name sortKey="Balow, Je" uniqKey="Balow J">JE Balow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, Hy" uniqKey="Wang H">HY Wang</name></author><author><name sortKey="Cui, Tg" uniqKey="Cui T">TG Cui</name></author><author><name sortKey="Hou, Ff" uniqKey="Hou F">FF Hou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Illei, Gg" uniqKey="Illei G">GG Illei</name></author><author><name sortKey="Austin, Ha" uniqKey="Austin H">HA Austin</name></author><author><name sortKey="Crane, M" uniqKey="Crane M">M Crane</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Houssiau, Fa" uniqKey="Houssiau F">FA Houssiau</name></author><author><name sortKey="Vasconcelos, C" uniqKey="Vasconcelos C">C Vasconcelos</name></author><author><name sortKey="D Cruz, D" uniqKey="D Cruz D">D D'Cruz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Appel, Gb" uniqKey="Appel G">GB Appel</name></author><author><name sortKey="Contreras, G" uniqKey="Contreras G">G Contreras</name></author><author><name sortKey="Dooley, Ma" uniqKey="Dooley M">MA Dooley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, Tm" uniqKey="Chan T">TM Chan</name></author><author><name sortKey="Li, Fk" uniqKey="Li F">FK Li</name></author><author><name sortKey="Tang, Cs" uniqKey="Tang C">CS Tang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, Tm" uniqKey="Chan T">TM Chan</name></author><author><name sortKey="Tse, Kc" uniqKey="Tse K">KC Tse</name></author><author><name sortKey="Tang, Cs" uniqKey="Tang C">CS Tang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ginzler, Em" uniqKey="Ginzler E">EM Ginzler</name></author><author><name sortKey="Dooley, Ma" uniqKey="Dooley M">MA Dooley</name></author><author><name sortKey="Aranow, C" uniqKey="Aranow C">C Aranow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Golshayan, D" uniqKey="Golshayan D">D Golshayan</name></author><author><name sortKey="Pascual, M" uniqKey="Pascual M">M Pascual</name></author><author><name sortKey="Vogt, B" uniqKey="Vogt B">B Vogt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sollinger, Hw" uniqKey="Sollinger H">HW Sollinger</name></author><author><name sortKey="Sundberg, Ak" uniqKey="Sundberg A">AK Sundberg</name></author><author><name sortKey="Leverson, G" uniqKey="Leverson G">G Leverson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zeher, M" uniqKey="Zeher M">M Zeher</name></author><author><name sortKey="Doria, A" uniqKey="Doria A">A Doria</name></author><author><name sortKey="Lan, J" uniqKey="Lan J">J Lan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Houssiau, Fa" uniqKey="Houssiau F">FA Houssiau</name></author><author><name sortKey="Vasconcelos, C" uniqKey="Vasconcelos C">C Vasconcelos</name></author><author><name sortKey="D Cruz, D" uniqKey="D Cruz D">D D'Cruz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Austin, Ha" uniqKey="Austin H">HA Austin</name></author><author><name sortKey="Illei, Gg" uniqKey="Illei G">GG Illei</name></author><author><name sortKey="Braun, Mj" uniqKey="Braun M">MJ Braun</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Radhakrishnan, J" uniqKey="Radhakrishnan J">J Radhakrishnan</name></author><author><name sortKey="Moutzouris, Da" uniqKey="Moutzouris D">DA Moutzouris</name></author><author><name sortKey="Ginzler, Em" uniqKey="Ginzler E">EM Ginzler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Isenberg, D" uniqKey="Isenberg D">D Isenberg</name></author><author><name sortKey="Appel, Gb" uniqKey="Appel G">GB Appel</name></author><author><name sortKey="Contreras, G" uniqKey="Contreras G">G Contreras</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ginzler, Em" uniqKey="Ginzler E">EM Ginzler</name></author><author><name sortKey="Felson, Dt" uniqKey="Felson D">DT Felson</name></author><author><name sortKey="Anthony, Jm" uniqKey="Anthony J">JM Anthony</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bakir, Aa" uniqKey="Bakir A">AA Bakir</name></author><author><name sortKey="Levy, Ps" uniqKey="Levy P">PS Levy</name></author><author><name sortKey="Dunea, G" uniqKey="Dunea G">G Dunea</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boumpas, Dt" uniqKey="Boumpas D">DT Boumpas</name></author><author><name sortKey="Austin, Ha" uniqKey="Austin H">HA Austin</name></author><author><name sortKey="Vaughn, Em" uniqKey="Vaughn E">EM Vaughn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grootscholten, C" uniqKey="Grootscholten C">C Grootscholten</name></author><author><name sortKey="Ligtenberg, G" uniqKey="Ligtenberg G">G Ligtenberg</name></author><author><name sortKey="Hagen, Ec" uniqKey="Hagen E">EC Hagen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shelp, Wd" uniqKey="Shelp W">WD Shelp</name></author><author><name sortKey="Bloodworth, Jm" uniqKey="Bloodworth J">JM Bloodworth</name></author><author><name sortKey="Rieselbach, Re" uniqKey="Rieselbach R">RE Rieselbach</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Badsha, H" uniqKey="Badsha H">H Badsha</name></author><author><name sortKey="Kong, Ko" uniqKey="Kong K">KO Kong</name></author><author><name sortKey="Lian, Ty" uniqKey="Lian T">TY Lian</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kong, Ko" uniqKey="Kong K">KO Kong</name></author><author><name sortKey="Badsha, H" uniqKey="Badsha H">H Badsha</name></author><author><name sortKey="Lian, Ty" uniqKey="Lian T">TY Lian</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kraft, Sw" uniqKey="Kraft S">SW Kraft</name></author><author><name sortKey="Schwartz, Mm" uniqKey="Schwartz M">MM Schwartz</name></author><author><name sortKey="Korbet, Sm" uniqKey="Korbet S">SM Korbet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Han, Ts" uniqKey="Han T">TS Han</name></author><author><name sortKey="Schwartz, Mm" uniqKey="Schwartz M">MM Schwartz</name></author><author><name sortKey="Lewis, Ej" uniqKey="Lewis E">EJ Lewis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marks, Sd" uniqKey="Marks S">SD Marks</name></author><author><name sortKey="Shah, V" uniqKey="Shah V">V Shah</name></author><author><name sortKey="Pilkington, C" uniqKey="Pilkington C">C Pilkington</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ter Borg, Ej" uniqKey="Ter Borg E">EJ ter Borg</name></author><author><name sortKey="De Jong, Pe" uniqKey="De Jong P">PE de Jong</name></author><author><name sortKey="Meijer, Ss" uniqKey="Meijer S">SS Meijer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Houssiau, Fa" uniqKey="Houssiau F">FA Houssiau</name></author><author><name sortKey="D Cruz, D" uniqKey="D Cruz D">D D'Cruz</name></author><author><name sortKey="Sangle, S" uniqKey="Sangle S">S Sangle</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dooley, Ma" uniqKey="Dooley M">MA Dooley</name></author><author><name sortKey="Jayne, D" uniqKey="Jayne D">D Jayne</name></author><author><name sortKey="Ginzler, Em" uniqKey="Ginzler E">EM Ginzler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moroni, G" uniqKey="Moroni G">G Moroni</name></author><author><name sortKey="Doria, A" uniqKey="Doria A">A Doria</name></author><author><name sortKey="Mosca, M" uniqKey="Mosca M">M Mosca</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Radhakrishnan, J" uniqKey="Radhakrishnan J">J Radhakrishnan</name></author><author><name sortKey="Kunis, Cl" uniqKey="Kunis C">CL Kunis</name></author><author><name sortKey="D Agati, V" uniqKey="D Agati V">V D'Agati</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schwartz, Mm" uniqKey="Schwartz M">MM Schwartz</name></author><author><name sortKey="Lan, Sp" uniqKey="Lan S">SP Lan</name></author><author><name sortKey="Bernstein, J" uniqKey="Bernstein J">J Bernstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gourley, Mf" uniqKey="Gourley M">MF Gourley</name></author><author><name sortKey="Austin, Ha" uniqKey="Austin H">HA Austin</name></author><author><name sortKey="Scott, D" uniqKey="Scott D">D Scott</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boumpas, Dt" uniqKey="Boumpas D">DT Boumpas</name></author><author><name sortKey="Austin, Ha" uniqKey="Austin H">HA Austin</name></author><author><name sortKey="Vaughan, Em" uniqKey="Vaughan E">EM Vaughan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Filler, G" uniqKey="Filler G">G Filler</name></author><author><name sortKey="Hansen, M" uniqKey="Hansen M">M Hansen</name></author><author><name sortKey="Leblanc, C" uniqKey="Leblanc C">C LeBlanc</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lertdumrongluk, P" uniqKey="Lertdumrongluk P">P Lertdumrongluk</name></author><author><name sortKey="Somparn, P" uniqKey="Somparn P">P Somparn</name></author><author><name sortKey="Kittanamongkolchai, W" uniqKey="Kittanamongkolchai W">W Kittanamongkolchai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zahr, N" uniqKey="Zahr N">N Zahr</name></author><author><name sortKey="Arnaud, L" uniqKey="Arnaud L">L Arnaud</name></author><author><name sortKey="Marquet, P" uniqKey="Marquet P">P Marquet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Karim, My" uniqKey="Karim M">MY Karim</name></author><author><name sortKey="Alba, P" uniqKey="Alba P">P Alba</name></author><author><name sortKey="Cuadrado, Mj" uniqKey="Cuadrado M">MJ Cuadrado</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moss, Ke" uniqKey="Moss K">KE Moss</name></author><author><name sortKey="Isenberg, Da" uniqKey="Isenberg D">DA Isenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Diaz Lagares, C" uniqKey="Diaz Lagares C">C Diaz-Lagares</name></author><author><name sortKey="Croca, S" uniqKey="Croca S">S Croca</name></author><author><name sortKey="Sangle, S" uniqKey="Sangle S">S Sangle</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ramos Casals, M" uniqKey="Ramos Casals M">M Ramos-Casals</name></author><author><name sortKey="Diaz Lagares, C" uniqKey="Diaz Lagares C">C Diaz-Lagares</name></author><author><name sortKey="Soto Cardenas, Mj" uniqKey="Soto Cardenas M">MJ Soto-Cardenas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cortes Hernandez, J" uniqKey="Cortes Hernandez J">J Cortes-Hernandez</name></author><author><name sortKey="Torres Salido, Mt" uniqKey="Torres Salido M">MT Torres-Salido</name></author><author><name sortKey="Medrano, As" uniqKey="Medrano A">AS Medrano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, T" uniqKey="Lee T">T Lee</name></author><author><name sortKey="Oh, Kh" uniqKey="Oh K">KH Oh</name></author><author><name sortKey="Joo, Kw" uniqKey="Joo K">KW Joo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Steinberg, Ad" uniqKey="Steinberg A">AD Steinberg</name></author><author><name sortKey="Kaltreider, Hb" uniqKey="Kaltreider H">HB Kaltreider</name></author><author><name sortKey="Staples, Pj" uniqKey="Staples P">PJ Staples</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Levy, Y" uniqKey="Levy Y">Y Levy</name></author><author><name sortKey="Sherer, Y" uniqKey="Sherer Y">Y Sherer</name></author><author><name sortKey="George, J" uniqKey="George J">J George</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Harada, T" uniqKey="Harada T">T Harada</name></author><author><name sortKey="Ozono, Y" uniqKey="Ozono Y">Y Ozono</name></author><author><name sortKey="Miyazaki, M" uniqKey="Miyazaki M">M Miyazaki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stummvoll, Gh" uniqKey="Stummvoll G">GH Stummvoll</name></author><author><name sortKey="Aringer, M" uniqKey="Aringer M">M Aringer</name></author><author><name sortKey="Smolen, Js" uniqKey="Smolen J">JS Smolen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stummvoll, Gh" uniqKey="Stummvoll G">GH Stummvoll</name></author><author><name sortKey="Schmaldienst, S" uniqKey="Schmaldienst S">S Schmaldienst</name></author><author><name sortKey="Smolen, Js" uniqKey="Smolen J">JS Smolen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tam, Ls" uniqKey="Tam L">LS Tam</name></author><author><name sortKey="Li, Ek" uniqKey="Li E">EK Li</name></author><author><name sortKey="Wong, Ck" uniqKey="Wong C">CK Wong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Petri, Ma" uniqKey="Petri M">MA Petri</name></author><author><name sortKey="Kiani, An" uniqKey="Kiani A">AN Kiani</name></author><author><name sortKey="Post, W" uniqKey="Post W">W Post</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Duran Barragan, S" uniqKey="Duran Barragan S">S Duran-Barragan</name></author><author><name sortKey="Mcgwin, G" uniqKey="Mcgwin G">G McGwin</name></author><author><name sortKey="Vila, Lm" uniqKey="Vila L">LM Vila</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kanda, H" uniqKey="Kanda H">H Kanda</name></author><author><name sortKey="Kubo, K" uniqKey="Kubo K">K Kubo</name></author><author><name sortKey="Tateishi, S" uniqKey="Tateishi S">S Tateishi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tse, Kc" uniqKey="Tse K">KC Tse</name></author><author><name sortKey="Li, Fk" uniqKey="Li F">FK Li</name></author><author><name sortKey="Tang, S" uniqKey="Tang S">S Tang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fessler, Bj" uniqKey="Fessler B">BJ Fessler</name></author><author><name sortKey="Alarcon, Gs" uniqKey="Alarcon G">GS Alarcon</name></author><author><name sortKey="Mcgwin, G" uniqKey="Mcgwin G">G McGwin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pons Estel, Gj" uniqKey="Pons Estel G">GJ Pons-Estel</name></author><author><name sortKey="Alarcon, Gs" uniqKey="Alarcon G">GS Alarcon</name></author><author><name sortKey="Mcgwin, G" uniqKey="Mcgwin G">G McGwin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tsakonas, E" uniqKey="Tsakonas E">E Tsakonas</name></author><author><name sortKey="Joseph, L" uniqKey="Joseph L">L Joseph</name></author><author><name sortKey="Esdaile, Jm" uniqKey="Esdaile J">JM Esdaile</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marmor, Mf" uniqKey="Marmor M">MF Marmor</name></author><author><name sortKey="Kellner, U" uniqKey="Kellner U">U Kellner</name></author><author><name sortKey="Lai, Ty" uniqKey="Lai T">TY Lai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Assen, S" uniqKey="Van Assen S">S van Assen</name></author><author><name sortKey="Agmon Levin, N" uniqKey="Agmon Levin N">N Agmon-Levin</name></author><author><name sortKey="Elkayam, O" uniqKey="Elkayam O">O Elkayam</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Heijstek, Mw" uniqKey="Heijstek M">MW Heijstek</name></author><author><name sortKey="Ott De Bruin, Lm" uniqKey="Ott De Bruin L">LM Ott de Bruin</name></author><author><name sortKey="Bijl, M" uniqKey="Bijl M">M Bijl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mosca, M" uniqKey="Mosca M">M Mosca</name></author><author><name sortKey="Tani, C" uniqKey="Tani C">C Tani</name></author><author><name sortKey="Aringer, M" uniqKey="Aringer M">M Aringer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nath, R" uniqKey="Nath R">R Nath</name></author><author><name sortKey="Mant, C" uniqKey="Mant C">C Mant</name></author><author><name sortKey="Luxton, J" uniqKey="Luxton J">J Luxton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nyberg, G" uniqKey="Nyberg G">G Nyberg</name></author><author><name sortKey="Eriksson, O" uniqKey="Eriksson O">O Eriksson</name></author><author><name sortKey="Westberg, Ng" uniqKey="Westberg N">NG Westberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fine, Dm" uniqKey="Fine D">DM Fine</name></author><author><name sortKey="Ziegenbein, M" uniqKey="Ziegenbein M">M Ziegenbein</name></author><author><name sortKey="Petri, M" uniqKey="Petri M">M Petri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hebert, La" uniqKey="Hebert L">LA Hebert</name></author><author><name sortKey="Birmingham, Dj" uniqKey="Birmingham D">DJ Birmingham</name></author><author><name sortKey="Shidham, G" uniqKey="Shidham G">G Shidham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leung, Yy" uniqKey="Leung Y">YY Leung</name></author><author><name sortKey="Szeto, Cc" uniqKey="Szeto C">CC Szeto</name></author><author><name sortKey="Tam, Ls" uniqKey="Tam L">LS Tam</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hebert, La" uniqKey="Hebert L">LA Hebert</name></author><author><name sortKey="Dillon, Jj" uniqKey="Dillon J">JJ Dillon</name></author><author><name sortKey="Middendorf, Df" uniqKey="Middendorf D">DF Middendorf</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moroni, G" uniqKey="Moroni G">G Moroni</name></author><author><name sortKey="Radice, A" uniqKey="Radice A">A Radice</name></author><author><name sortKey="Giammarresi, G" uniqKey="Giammarresi G">G Giammarresi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Birmingham, Dj" uniqKey="Birmingham D">DJ Birmingham</name></author><author><name sortKey="Irshaid, F" uniqKey="Irshaid F">F Irshaid</name></author><author><name sortKey="Nagaraja, Hn" uniqKey="Nagaraja H">HN Nagaraja</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Esdaile, Jm" uniqKey="Esdaile J">JM Esdaile</name></author><author><name sortKey="Abrahamowicz, M" uniqKey="Abrahamowicz M">M Abrahamowicz</name></author><author><name sortKey="Joseph, L" uniqKey="Joseph L">L Joseph</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ghirardello, A" uniqKey="Ghirardello A">A Ghirardello</name></author><author><name sortKey="Villalta, D" uniqKey="Villalta D">D Villalta</name></author><author><name sortKey="Morozzi, G" uniqKey="Morozzi G">G Morozzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jaekell, Hp" uniqKey="Jaekell H">HP Jaekell</name></author><author><name sortKey="Trabandt, A" uniqKey="Trabandt A">A Trabandt</name></author><author><name sortKey="Grobe, N" uniqKey="Grobe N">N Grobe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grootscholten, C" uniqKey="Grootscholten C">C Grootscholten</name></author><author><name sortKey="Dieker, Jw" uniqKey="Dieker J">JW Dieker</name></author><author><name sortKey="Mcgrath, Fd" uniqKey="Mcgrath F">FD McGrath</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gutierrez Adrianzen, Oa" uniqKey="Gutierrez Adrianzen O">OA Gutierrez-Adrianzen</name></author><author><name sortKey="Koutouzov, S" uniqKey="Koutouzov S">S Koutouzov</name></author><author><name sortKey="Mota, Rm" uniqKey="Mota R">RM Mota</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mok, Cc" uniqKey="Mok C">CC Mok</name></author><author><name sortKey="Ho, Ly" uniqKey="Ho L">LY Ho</name></author><author><name sortKey="Leung, Hw" uniqKey="Leung H">HW Leung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Der Vlag, J" uniqKey="Van Der Vlag J">J van der Vlag</name></author><author><name sortKey="Berden, Jh" uniqKey="Berden J">JH Berden</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Steinberg, Ad" uniqKey="Steinberg A">AD Steinberg</name></author><author><name sortKey="Decker, Jl" uniqKey="Decker J">JL Decker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hill, Gs" uniqKey="Hill G">GS Hill</name></author><author><name sortKey="Delahousse, M" uniqKey="Delahousse M">M Delahousse</name></author><author><name sortKey="Nochy, D" uniqKey="Nochy D">D Nochy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hill, Gs" uniqKey="Hill G">GS Hill</name></author><author><name sortKey="Delahousse, M" uniqKey="Delahousse M">M Delahousse</name></author><author><name sortKey="Nochy, D" uniqKey="Nochy D">D Nochy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moroni, G" uniqKey="Moroni G">G Moroni</name></author><author><name sortKey="Pasquali, S" uniqKey="Pasquali S">S Pasquali</name></author><author><name sortKey="Quaglini, S" uniqKey="Quaglini S">S Quaglini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Balow, Je" uniqKey="Balow J">JE Balow</name></author><author><name sortKey="Austin, Ha" uniqKey="Austin H">HA Austin</name></author><author><name sortKey="Muenz, Lr" uniqKey="Muenz L">LR Muenz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Correia, P" uniqKey="Correia P">P Correia</name></author><author><name sortKey="Cameron, Js" uniqKey="Cameron J">JS Cameron</name></author><author><name sortKey="Lian, Jd" uniqKey="Lian J">JD Lian</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Perkins, Rm" uniqKey="Perkins R">RM Perkins</name></author><author><name sortKey="Reynolds, Jc" uniqKey="Reynolds J">JC Reynolds</name></author><author><name sortKey="Ahuja, Ts" uniqKey="Ahuja T">TS Ahuja</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Siu, Yp" uniqKey="Siu Y">YP Siu</name></author><author><name sortKey="Leung, Kt" uniqKey="Leung K">KT Leung</name></author><author><name sortKey="Tong, Mk" uniqKey="Tong M">MK Tong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weng, Ch" uniqKey="Weng C">CH Weng</name></author><author><name sortKey="Hsu, Cw" uniqKey="Hsu C">CW Hsu</name></author><author><name sortKey="Yu, Cc" uniqKey="Yu C">CC Yu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nossent, Hc" uniqKey="Nossent H">HC Nossent</name></author><author><name sortKey="Swaak, Tj" uniqKey="Swaak T">TJ Swaak</name></author><author><name sortKey="Berden, Jh" uniqKey="Berden J">JH Berden</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ribeiro, Fm" uniqKey="Ribeiro F">FM Ribeiro</name></author><author><name sortKey="Leite, Ma" uniqKey="Leite M">MA Leite</name></author><author><name sortKey="Velarde, Gc" uniqKey="Velarde G">GC Velarde</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rodby, Ra" uniqKey="Rodby R">RA Rodby</name></author><author><name sortKey="Korbet, Sm" uniqKey="Korbet S">SM Korbet</name></author><author><name sortKey="Lewis, Ej" uniqKey="Lewis E">EJ Lewis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Szeto, Cc" uniqKey="Szeto C">CC Szeto</name></author><author><name sortKey="Li, Pk" uniqKey="Li P">PK Li</name></author><author><name sortKey="Wong, Ty" uniqKey="Wong T">TY Wong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Okano, K" uniqKey="Okano K">K Okano</name></author><author><name sortKey="Yumura, W" uniqKey="Yumura W">W Yumura</name></author><author><name sortKey="Nitta, K" uniqKey="Nitta K">K Nitta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sires, Rl" uniqKey="Sires R">RL Sires</name></author><author><name sortKey="Adler, Sg" uniqKey="Adler S">SG Adler</name></author><author><name sortKey="Louie, Js" uniqKey="Louie J">JS Louie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rietveld, A" uniqKey="Rietveld A">A Rietveld</name></author><author><name sortKey="Berden, Jh" uniqKey="Berden J">JH Berden</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bunnapradist, S" uniqKey="Bunnapradist S">S Bunnapradist</name></author><author><name sortKey="Chung, P" uniqKey="Chung P">P Chung</name></author><author><name sortKey="Peng, A" uniqKey="Peng A">A Peng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chelamcharla, M" uniqKey="Chelamcharla M">M Chelamcharla</name></author><author><name sortKey="Javaid, B" uniqKey="Javaid B">B Javaid</name></author><author><name sortKey="Baird, Bc" uniqKey="Baird B">BC Baird</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="El Shahawy, Ma" uniqKey="El Shahawy M">MA el-Shahawy</name></author><author><name sortKey="Aswad, S" uniqKey="Aswad S">S Aswad</name></author><author><name sortKey="Mendez, Rg" uniqKey="Mendez R">RG Mendez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Goral, S" uniqKey="Goral S">S Goral</name></author><author><name sortKey="Ynares, C" uniqKey="Ynares C">C Ynares</name></author><author><name sortKey="Shappell, Sb" uniqKey="Shappell S">SB Shappell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Signori Baracat, Al" uniqKey="Signori Baracat A">AL Signori Baracat</name></author><author><name sortKey="Ribeiro Alves, Ma" uniqKey="Ribeiro Alves M">MA Ribeiro-Alves</name></author><author><name sortKey="Alves Filho, G" uniqKey="Alves Filho G">G Alves-Filho</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Contreras, G" uniqKey="Contreras G">G Contreras</name></author><author><name sortKey="Mattiazzi, A" uniqKey="Mattiazzi A">A Mattiazzi</name></author><author><name sortKey="Guerra, G" uniqKey="Guerra G">G Guerra</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stone, Jh" uniqKey="Stone J">JH Stone</name></author><author><name sortKey="Amend, Wj" uniqKey="Amend W">WJ Amend</name></author><author><name sortKey="Criswell, La" uniqKey="Criswell L">LA Criswell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tang, H" uniqKey="Tang H">H Tang</name></author><author><name sortKey="Chelamcharla, M" uniqKey="Chelamcharla M">M Chelamcharla</name></author><author><name sortKey="Baird, Bc" uniqKey="Baird B">BC Baird</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Naveed, A" uniqKey="Naveed A">A Naveed</name></author><author><name sortKey="Nilubol, C" uniqKey="Nilubol C">C Nilubol</name></author><author><name sortKey="Melancon, Jk" uniqKey="Melancon J">JK Melancon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moroni, G" uniqKey="Moroni G">G Moroni</name></author><author><name sortKey="Tantardini, F" uniqKey="Tantardini F">F Tantardini</name></author><author><name sortKey="Gallelli, B" uniqKey="Gallelli B">B Gallelli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stone, Jh" uniqKey="Stone J">JH Stone</name></author><author><name sortKey="Amend, Wj" uniqKey="Amend W">WJ Amend</name></author><author><name sortKey="Criswell, La" uniqKey="Criswell L">LA Criswell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vaidya, S" uniqKey="Vaidya S">S Vaidya</name></author><author><name sortKey="Sellers, R" uniqKey="Sellers R">R Sellers</name></author><author><name sortKey="Kimball, P" uniqKey="Kimball P">P Kimball</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vaidya, S" uniqKey="Vaidya S">S Vaidya</name></author><author><name sortKey="Wang, Cc" uniqKey="Wang C">CC Wang</name></author><author><name sortKey="Gugliuzza, C" uniqKey="Gugliuzza C">C Gugliuzza</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burgos, Pi" uniqKey="Burgos P">PI Burgos</name></author><author><name sortKey="Perkins, El" uniqKey="Perkins E">EL Perkins</name></author><author><name sortKey="Pons Estel, Gj" uniqKey="Pons Estel G">GJ Pons-Estel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Norby, Ge" uniqKey="Norby G">GE Norby</name></author><author><name sortKey="Strom, Eh" uniqKey="Strom E">EH Strom</name></author><author><name sortKey="Midtvedt, K" uniqKey="Midtvedt K">K Midtvedt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tektonidou, Mg" uniqKey="Tektonidou M">MG Tektonidou</name></author><author><name sortKey="Sotsiou, F" uniqKey="Sotsiou F">F Sotsiou</name></author><author><name sortKey="Nakopoulou, L" uniqKey="Nakopoulou L">L Nakopoulou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galindo, M" uniqKey="Galindo M">M Galindo</name></author><author><name sortKey="Gonzalo, E" uniqKey="Gonzalo E">E Gonzalo</name></author><author><name sortKey="Martinez Vidal, Mp" uniqKey="Martinez Vidal M">MP Martinez-Vidal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shen, Ym" uniqKey="Shen Y">YM Shen</name></author><author><name sortKey="Lee, R" uniqKey="Lee R">R Lee</name></author><author><name sortKey="Frenkel, E" uniqKey="Frenkel E">E Frenkel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zheng, H" uniqKey="Zheng H">H Zheng</name></author><author><name sortKey="Chen, Y" uniqKey="Chen Y">Y Chen</name></author><author><name sortKey="Ao, W" uniqKey="Ao W">W Ao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheunsuchon, B" uniqKey="Cheunsuchon B">B Cheunsuchon</name></author><author><name sortKey="Rungkaew, P" uniqKey="Rungkaew P">P Rungkaew</name></author><author><name sortKey="Chawanasuntorapoj, R" uniqKey="Chawanasuntorapoj R">R Chawanasuntorapoj</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ruiz Irastorza, G" uniqKey="Ruiz Irastorza G">G Ruiz-Irastorza</name></author><author><name sortKey="Cuadrado, Mj" uniqKey="Cuadrado M">MJ Cuadrado</name></author><author><name sortKey="Ruiz Arruza, I" uniqKey="Ruiz Arruza I">I Ruiz-Arruza</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Clowse, Me" uniqKey="Clowse M">ME Clowse</name></author><author><name sortKey="Magder, L" uniqKey="Magder L">L Magder</name></author><author><name sortKey="Witter, F" uniqKey="Witter F">F Witter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Clowse, Me" uniqKey="Clowse M">ME Clowse</name></author><author><name sortKey="Magder, Ls" uniqKey="Magder L">LS Magder</name></author><author><name sortKey="Witter, F" uniqKey="Witter F">F Witter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kwok, Lw" uniqKey="Kwok L">LW Kwok</name></author><author><name sortKey="Tam, Ls" uniqKey="Tam L">LS Tam</name></author><author><name sortKey="Zhu, T" uniqKey="Zhu T">T Zhu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Imbasciati, E" uniqKey="Imbasciati E">E Imbasciati</name></author><author><name sortKey="Tincani, A" uniqKey="Tincani A">A Tincani</name></author><author><name sortKey="Gregorini, G" uniqKey="Gregorini G">G Gregorini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carmona, F" uniqKey="Carmona F">F Carmona</name></author><author><name sortKey="Font, J" uniqKey="Font J">J Font</name></author><author><name sortKey="Moga, I" uniqKey="Moga I">I Moga</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smyth, A" uniqKey="Smyth A">A Smyth</name></author><author><name sortKey="Oliveira, Gh" uniqKey="Oliveira G">GH Oliveira</name></author><author><name sortKey="Lahr, Bd" uniqKey="Lahr B">BD Lahr</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Buyon, Jp" uniqKey="Buyon J">JP Buyon</name></author><author><name sortKey="Cronstein, Bn" uniqKey="Cronstein B">BN Cronstein</name></author><author><name sortKey="Morris, M" uniqKey="Morris M">M Morris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Huong, Dl" uniqKey="Huong D">DL Huong</name></author><author><name sortKey="Wechsler, B" uniqKey="Wechsler B">B Wechsler</name></author><author><name sortKey="Vauthier Brouzes, D" uniqKey="Vauthier Brouzes D">D Vauthier-Brouzes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chakravarty, Ef" uniqKey="Chakravarty E">EF Chakravarty</name></author><author><name sortKey="Colon, I" uniqKey="Colon I">I Colon</name></author><author><name sortKey="Langen, Es" uniqKey="Langen E">ES Langen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Livingston, B" uniqKey="Livingston B">B Livingston</name></author><author><name sortKey="Bonner, A" uniqKey="Bonner A">A Bonner</name></author><author><name sortKey="Pope, J" uniqKey="Pope J">J Pope</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rzany, B" uniqKey="Rzany B">B Rzany</name></author><author><name sortKey="Coresh, J" uniqKey="Coresh J">J Coresh</name></author><author><name sortKey="Whelton, Pk" uniqKey="Whelton P">PK Whelton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ravelli, A" uniqKey="Ravelli A">A Ravelli</name></author><author><name sortKey="Duarte Salazar, C" uniqKey="Duarte Salazar C">C Duarte-Salazar</name></author><author><name sortKey="Buratti, S" uniqKey="Buratti S">S Buratti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brunner, Hi" uniqKey="Brunner H">HI Brunner</name></author><author><name sortKey="Gladman, Dd" uniqKey="Gladman D">DD Gladman</name></author><author><name sortKey="Ibanez, D" uniqKey="Ibanez D">D Ibanez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hiraki, Lt" uniqKey="Hiraki L">LT Hiraki</name></author><author><name sortKey="Benseler, Sm" uniqKey="Benseler S">SM Benseler</name></author><author><name sortKey="Tyrrell, Pn" uniqKey="Tyrrell P">PN Tyrrell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hersh, Ao" uniqKey="Hersh A">AO Hersh</name></author><author><name sortKey="Von Scheven, E" uniqKey="Von Scheven E">E von Scheven</name></author><author><name sortKey="Yazdany, J" uniqKey="Yazdany J">J Yazdany</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Taddio, A" uniqKey="Taddio A">A Taddio</name></author><author><name sortKey="Rossetto, E" uniqKey="Rossetto E">E Rossetto</name></author><author><name sortKey="Rose, Cd" uniqKey="Rose C">CD Rose</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Traynor, Ae" uniqKey="Traynor A">AE Traynor</name></author><author><name sortKey="Schroeder, J" uniqKey="Schroeder J">J Schroeder</name></author><author><name sortKey="Rosa, Rm" uniqKey="Rosa R">RM Rosa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fu, Lw" uniqKey="Fu L">LW Fu</name></author><author><name sortKey="Yang, Ly" uniqKey="Yang L">LY Yang</name></author><author><name sortKey="Chen, Wp" uniqKey="Chen W">WP Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lau, Kk" uniqKey="Lau K">KK Lau</name></author><author><name sortKey="Ault, Bh" uniqKey="Ault B">BH Ault</name></author><author><name sortKey="Jones, Dp" uniqKey="Jones D">DP Jones</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Urowitz, Mb" uniqKey="Urowitz M">MB Urowitz</name></author><author><name sortKey="Ibanez, D" uniqKey="Ibanez D">D Ibanez</name></author><author><name sortKey="Ali, Y" uniqKey="Ali Y">Y Ali</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Rheum Dis</journal-id><journal-id journal-id-type="iso-abbrev">Ann. Rheum. Dis</journal-id><journal-id journal-id-type="hwp">annrheumdis</journal-id><journal-id journal-id-type="publisher-id">ard</journal-id><journal-title-group><journal-title>Annals of the Rheumatic Diseases</journal-title></journal-title-group><issn pub-type="ppub">0003-4967</issn><issn pub-type="epub">1468-2060</issn><publisher><publisher-name>BMJ Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22851469</article-id><article-id pub-id-type="pmc">3465859</article-id><article-id pub-id-type="publisher-id">annrheumdis-2012-201940</article-id><article-id pub-id-type="doi">10.1136/annrheumdis-2012-201940</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject></subj-group><subj-group subj-group-type="heading"><subject>Recommendations</subject></subj-group></article-categories><title-group><article-title>Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis</article-title><alt-title alt-title-type="short">Recommendation</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bertsias</surname><given-names>George K</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tektonidou</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Amoura</surname><given-names>Zahir</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Aringer</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Bajema</surname><given-names>Ingeborg</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Berden</surname><given-names>Jo H M</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Boletis</surname><given-names>John</given-names></name><xref ref-type="aff" rid="af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Cervera</surname><given-names>Ricard</given-names></name><xref ref-type="aff" rid="af8">8</xref></contrib><contrib contrib-type="author"><name><surname>Dörner</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="af9">9</xref></contrib><contrib contrib-type="author"><name><surname>Doria</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="af10">10</xref></contrib><contrib contrib-type="author"><name><surname>Ferrario</surname><given-names>Franco</given-names></name><xref ref-type="aff" rid="af11">11</xref></contrib><contrib contrib-type="author"><name><surname>Floege</surname><given-names>Jürgen</given-names></name><xref ref-type="aff" rid="af12">12</xref></contrib><contrib contrib-type="author"><name><surname>Houssiau</surname><given-names>Frederic A</given-names></name><xref ref-type="aff" rid="af13">13</xref></contrib><contrib contrib-type="author"><name><surname>Ioannidis</surname><given-names>John P A</given-names></name><xref ref-type="aff" rid="af14">14</xref></contrib><contrib contrib-type="author"><name><surname>Isenberg</surname><given-names>David A</given-names></name><xref ref-type="aff" rid="af15">15</xref></contrib><contrib contrib-type="author"><name><surname>Kallenberg</surname><given-names>Cees G M</given-names></name><xref ref-type="aff" rid="af16">16</xref></contrib><contrib contrib-type="author"><name><surname>Lightstone</surname><given-names>Liz</given-names></name><xref ref-type="aff" rid="af17">17</xref></contrib><contrib contrib-type="author"><name><surname>Marks</surname><given-names>Stephen D</given-names></name><xref ref-type="aff" rid="af18">18</xref></contrib><contrib contrib-type="author"><name><surname>Martini</surname><given-names>Alberto</given-names></name><xref ref-type="aff" rid="af19">19</xref></contrib><contrib contrib-type="author"><name><surname>Moroni</surname><given-names>Gabriela</given-names></name><xref ref-type="aff" rid="af20">20</xref></contrib><contrib contrib-type="author"><name><surname>Neumann</surname><given-names>Irmgard</given-names></name><xref ref-type="aff" rid="af21">21</xref></contrib><contrib contrib-type="author"><name><surname>Praga</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="af22">22</xref></contrib><contrib contrib-type="author"><name><surname>Schneider</surname><given-names>Matthias</given-names></name><xref ref-type="aff" rid="af23">23</xref></contrib><contrib contrib-type="author"><name><surname>Starra</surname><given-names>Argyre</given-names></name><xref ref-type="aff" rid="af24">24</xref></contrib><contrib contrib-type="author"><name><surname>Tesar</surname><given-names>Vladimir</given-names></name><xref ref-type="aff" rid="af25">25</xref></contrib><contrib contrib-type="author"><name><surname>Vasconcelos</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="af26">26</xref></contrib><contrib contrib-type="author"><name><surname>van Vollenhoven</surname><given-names>Ronald F</given-names></name><xref ref-type="aff" rid="af27">27</xref></contrib><contrib contrib-type="author"><name><surname>Zakharova</surname><given-names>Helena</given-names></name><xref ref-type="aff" rid="af28">28</xref></contrib><contrib contrib-type="author"><name><surname>Haubitz</surname><given-names>Marion</given-names></name><xref ref-type="aff" rid="af29">29</xref></contrib><contrib contrib-type="author"><name><surname>Gordon</surname><given-names>Caroline</given-names></name><xref ref-type="aff" rid="af30">30</xref></contrib><contrib contrib-type="author"><name><surname>Jayne</surname><given-names>David</given-names></name><xref ref-type="aff" rid="af31">31</xref></contrib><contrib contrib-type="author"><name><surname>Boumpas</surname><given-names>Dimitrios T</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib></contrib-group><aff id="af1"><label>1</label>Department of Medicine, Rheumatology, Clinical Immunology and Allergy, University of Crete, Iraklion, Greece</aff><aff id="af2"><label>2</label>First Department of Internal Medicine, Rheumatology, University of Athens, Athens, Greece</aff><aff id="af3"><label>3</label>Department of Internal Medicine, French National Reference Center for SLE, Université Paris VI Pierre et Marie Curie, Hôpital Pitié-Salpêtrière, Paris, France</aff><aff id="af4"><label>4</label>Division of Rheumatology, Department of Medicine III, University Medical Center Carl Gustav Carus, Dresden, Germany</aff><aff id="af5"><label>5</label>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands</aff><aff id="af6"><label>6</label>Department of Nephrology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands</aff><aff id="af7"><label>7</label>Department of Nephrology and Transplantation Center, Laiko General Hospital, Athens, Greece</aff><aff id="af8"><label>8</label>Department of Autoimmune Diseases, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain</aff><aff id="af9"><label>9</label>Department of Medicine, Rheumatology and Clinical Immunology, Charité—University Medicine Berlin, Berlin, Germany</aff><aff id="af10"><label>10</label>Division of Rheumatology, Department of Medicine, University of Padova, Padova, Italy</aff><aff id="af11"><label>11</label>Nephropathology Center, San Gerardo Hospital, Monza and Milan Bicocca University, Monza, Italy</aff><aff id="af12"><label>12</label>Division of Nephrology and Clinical Immunology, RWTH University of Aachen, Aachen, Germany</aff><aff id="af13"><label>13</label>Department of Rheumatology, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Bruxelles, Belgium</aff><aff id="af14"><label>14</label>Stanford Prevention Research Center, Department of Medicine, and Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California, USA</aff><aff id="af15"><label>15</label>Centre for Rheumatology Research, Division of Medicine, University College London, London, UK</aff><aff id="af16"><label>16</label>Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands</aff><aff id="af17"><label>17</label>Section of Renal Medicine, Division of Immunology and Inflammation, Department of Medicine, Imperial College London, London, UK</aff><aff id="af18"><label>18</label>Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Trust, London, UK</aff><aff id="af19"><label>19</label>Pediatria II, Reumatologia, IRCCS Istituto G Gaslini, Università di Genova, Genova, Italy</aff><aff id="af20"><label>20</label>Divisione di Nefrologia e Dialisi Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy</aff><aff id="af21"><label>21</label>Division of Nephrology, Internal Medicine, Wilhelminenspital, Vienna, Austria</aff><aff id="af22"><label>22</label>Nephrology Division, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain</aff><aff id="af23"><label>23</label>Department of Medicine, Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany</aff><aff id="af24"><label>24</label><italic>Patient representative</italic> (Iraklio), Rethymnon, Greece</aff><aff id="af25"><label>25</label>Department of Nephrology, First School of Medicine, Charles University, Prague, Czech Republic</aff><aff id="af26"><label>26</label>Unidade de Imunologia Clinica, Hospital Santo Antonio, Centro Hospitalar do Porto, UMIB-ICBAS, Universidade do Porto, Porto, Portugal</aff><aff id="af27"><label>27</label>Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Stockholm, Sweden</aff><aff id="af28"><label>28</label>Nephrology Unit, Moscow City Hospital n.a. S.P. Botkin, Moscow State Medicine and Dentistry University, Moscow, Russian Federation</aff><aff id="af29"><label>29</label>Department of Nephrology and Hypertension, Hannover Medical School, Hannover and Klinikum Fulda, Fulda, Germany</aff><aff id="af30"><label>30</label>Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, West Midlands, UK</aff><aff id="af31"><label>31</label>Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK</aff><author-notes><corresp><label>Correspondence to</label> Dr Dimitrios T Boumpas, Department of Rheumatology, Clinical Immunology, and Allergy, University of Crete, Faculty of Medicine, Iraklio, Greece; <email>boumpasd@med.uoc.gr</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>31</day><month>7</month><year>2012</year></pub-date><volume>71</volume><issue>11</issue><fpage>1771</fpage><lpage>1782</lpage><history><date date-type="received"><day>27</day><month>3</month><year>2012</year></date><date date-type="accepted"><day>3</day><month>7</month><year>2012</year></date></history><permissions><copyright-statement>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/legalcode">http://creativecommons.org/licenses/by-nc/3.0/legalcode</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="annrheumdis-2012-201940.pdf"></self-uri><abstract><sec><title>Objectives</title><p>To develop recommendations for the management of adult and paediatric lupus nephritis (LN).</p></sec><sec><title>Methods</title><p>The available evidence was systematically reviewed using the PubMed database. A modified Delphi method was used to compile questions, elicit expert opinions and reach consensus.</p></sec><sec><title>Results</title><p>Immunosuppressive treatment should be guided by renal biopsy, and aiming for complete renal response (proteinuria <0.5 g/24 h with normal or near-normal renal function). Hydroxychloroquine is recommended for all patients with LN. Because of a more favourable efficacy/toxicity ratio, as initial treatment for patients with class III–IV<sub>A</sub> or <sub>A/C</sub> (±V) LN according to the International Society of Nephrology/Renal Pathology Society 2003 classification, mycophenolic acid (MPA) or low-dose intravenous cyclophosphamide (CY) in combination with glucocorticoids is recommended. In patients with adverse clinical or histological features, CY can be prescribed at higher doses, while azathioprine is an alternative for milder cases. For pure class V LN with nephrotic-range proteinuria, MPA in combination with oral glucocorticoids is recommended as initial treatment. In patients improving after initial treatment, subsequent immunosuppression with MPA or azathioprine is recommended for at least 3 years; in such cases, initial treatment with MPA should be followed by MPA. For MPA or CY failures, switching to the other agent, or to rituximab, is the suggested course of action. In anticipation of pregnancy, patients should be switched to appropriate medications without reducing the intensity of treatment. There is no evidence to suggest that management of LN should differ in children versus adults.</p></sec><sec><title>Conclusions</title><p>Recommendations for the management of LN were developed using an evidence-based approach followed by expert consensus.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Approximately 50% of patients with systemic lupus erythematosus (SLE) will develop lupus nephritis (LN), which increases the risks for renal failure, cardiovascular disease and death. In 2008, we published the first European League Against Rheumatism (EULAR) recommendations on the management of SLE.<xref ref-type="bibr" rid="R1">1</xref> Since then, several controlled trials have been published upon which updated recommendations can be based. The realisation that in the care of patients with LN internists/rheumatologists and nephrologists are involved, prompted us to develop recommendations for LN under the joint auspices of the EULAR and the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA), with experts from both disciplines. The panel was enriched with renal pathologists and paediatricians with expertise on LN.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>We followed the EULAR standardised operating procedures<xref ref-type="bibr" rid="R2">2</xref> and the Appraisal of Guidelines Research and Evaluation instrument. We selected a list of questions by a modified Delphi method further edited for literature search, followed by a systematic search of the PubMed database (<ext-link ext-link-type="uri" xlink:href="http://.oxfordjournals.org/lookup/suppl/doi:10.1093//annrheumdis-2012-201940/-/DC1">web-only appendix tables 1 and 2</ext-link>); all English language publications up to December 2011 were considered. We further refined retrieved items based on abstract and/or full-text content, and the number of patients (requiring n≥30 for diagnosis, monitoring, prognosis; n<italic> </italic>≥ 10 for treatment). A detailed presentation of the literature review is provided in <ext-link ext-link-type="uri" xlink:href="http://.oxfordjournals.org/lookup/suppl/doi:10.1093//annrheumdis-2012-201940/-/DC1">web-only appendix table 3</ext-link>. Evidence was categorised based on the design and validity of available studies and the strength of the statements was graded. After discussions, the committee arrived at 28 final statements rated individually by each member (<xref ref-type="table" rid="annrheumdis2012201940TB1 annrheumdis2012201940TB2">tables 1 and 2</xref>).</p><table-wrap id="annrheumdis2012201940TB1" position="float"><label>Table 1</label><caption><p>Recommendations for the management of patients with systemic lupus erythematosus (SLE) with renal involvement</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col></colgroup><thead><tr><th rowspan="1" colspan="1">Statement</th><th rowspan="1" colspan="1">Mean (SD)</th><th rowspan="1" colspan="1">Median (IQR)*</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">1. Indications for first renal biopsy in SLE</td></tr><tr><td rowspan="1" colspan="1"> Any sign of renal involvement—in particular, urinary findings such as reproducible proteinuria ≥0.5 g/24 h especially with glomerular haematuria and/or cellular casts—should be an indication for renal biopsy. Renal biopsy is indispensable since in most cases, clinical, serological or laboratory tests cannot accurately predict renal biopsy findings.</td><td rowspan="1" colspan="1">9.7 (0.5)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td colspan="3" rowspan="1">2. Pathological assessment of kidney biopsy</td></tr><tr><td rowspan="1" colspan="1"> The use of the International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification system is recommended with assessment of active and chronic glomerular and tubulointerstitial changes, and of vascular lesions associated with anti-phospholipid antibodies/syndrome</td><td rowspan="1" colspan="1">9.6 (0.7)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td colspan="3" rowspan="1">3. Indications and goals of immunosuppressive treatment in lupus nephritis (LN)</td></tr><tr><td rowspan="1" colspan="1"> 3.1. Initiation of immunosuppressive treatment should be guided by a diagnostic renal biopsy. Immunosuppressive agents are recommended in class III<sub>A</sub> or III<sub>A/C</sub> (±V) and IV<sub>A</sub> or IV<sub>A/C</sub> (±V) nephritis, and also in pure class V nephritis if proteinuria exceeds 1 g/24 h despite the optimal use of renin-angiotensin-aldosterone system blockers</td><td rowspan="1" colspan="1">9.4 (0.7)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td rowspan="1" colspan="1"> 3.2. The ultimate goals of treatment in LN are long-term preservation of renal function, prevention of disease flares, avoidance of treatment-related harms, and improved quality of life and survival. Treatment should aim for complete renal response with UPCR <50 mg/mol and normal or near-normal (within 10% of normal GFR if previously abnormal) renal function. Partial renal response, defined as ≥50% reduction in proteinuria to subnephrotic levels and normal or near-normal renal function, should be achieved preferably by 6 months but no later than 12 months following initiation of treatment</td><td rowspan="1" colspan="1">9.6 (0.8)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td colspan="3" rowspan="1">4. Treatment of adult LN</td></tr><tr><td colspan="3" rowspan="1"> Initial treatment</td></tr><tr><td rowspan="1" colspan="1"> 4.1. For patients with class III<sub>A</sub> or III<sub>A/C</sub> (±V) and class IV<sub>A</sub> or IV<sub>A/C</sub> (±V) LN, mycophenolic acid (MPA) (mycophenolate mofetil (MMF) target dose: 3 g/day for 6 months, or MPA sodium at equivalent dose) or low-dose intravenous cyclophosphamide (CY) (total dose 3 g over 3 months) in combination with glucocorticoids, are recommended as initial treatment as they have the best efficacy/toxicity ratio</td><td rowspan="1" colspan="1">9.3 (0.8)</td><td rowspan="1" colspan="1">9 (1)</td></tr><tr><td rowspan="1" colspan="1"> 4.2. In patients with adverse prognostic factors (acute deterioration in renal function, substantial cellular crescents and/or fibrinoid necrosis), similar regimens may be used but CY can also be prescribed monthly at higher doses (0.75–1 g/m<sup>2</sup>) for 6 months or orally (2–2.5 mg/kg/day) for 3 months</td><td rowspan="1" colspan="1">8.8 (1.3)</td><td rowspan="1" colspan="1">9 (2)</td></tr><tr><td rowspan="1" colspan="1"> 4.3. To increase efficacy and reduce cumulative glucocorticoid doses, treatment regimens should be combined initially with three consecutive pulses of intravenous methylprednisolone 500–750 mg, followed by oral prednisone 0.5 mg/kg/day for 4 weeks, reducing to ≤10 mg/day by 4–6 months</td><td rowspan="1" colspan="1">9.0 (1.1)</td><td rowspan="1" colspan="1">9 (2)</td></tr><tr><td rowspan="1" colspan="1"> 4.4. In pure class V nephritis with nephrotic-range proteinuria, MPA (MMF target dose 3 g/day for 6 months) in combination with oral prednisone (0.5 mg/kg/day) may be used as initial treatment based on better efficacy/toxicity ratio. CY or calcineurin inhibitors (ciclosporin, tacrolimus) or rituximab are recommended as alternative options or for non-responders.</td><td rowspan="1" colspan="1">8.9 (1.2)</td><td rowspan="1" colspan="1">9 (2)</td></tr><tr><td rowspan="1" colspan="1"> 4.5. Azathioprine (AZA) (2 mg/kg/day) may be considered as an alternative to MPA or CY in selected patients without adverse prognostic factors (as defined in 4.2), or when these drugs are contraindicated, not tolerated or unavailable. Azathioprine use is associated with a higher flare risk.</td><td rowspan="1" colspan="1">8.6 (1.3)</td><td rowspan="1" colspan="1">9 (2)</td></tr><tr><td colspan="3" rowspan="1"> Subsequent treatment</td></tr><tr><td rowspan="1" colspan="1"> 4.6. In patients improving after initial treatment, subsequent immunosuppression is recommended with either MPA at lower doses (initial target MMF dose 2 g/day) or AZA (2 mg/kg/day) for at least 3 years, in combination with low dose prednisone (5–7.5 mg/day). Gradual drug withdrawal, glucocorticoids first, can then be attempted.</td><td rowspan="1" colspan="1">9.4 (0.9)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td rowspan="1" colspan="1"> 4.7. Patients who responded to initial treatment with MPA should remain on MPA unless pregnancy is contemplated, in which case they should switch to AZA at least 3 months prior to conception</td><td rowspan="1" colspan="1">9.4 (0.8)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td rowspan="1" colspan="1"> 4.8. Calcineurin inhibitors can be considered in pure class V nephritis</td><td rowspan="1" colspan="1">9.1 (1.2)</td><td rowspan="1" colspan="1">10 (2)</td></tr><tr><td colspan="3" rowspan="1"> Refractory disease</td></tr><tr><td rowspan="1" colspan="1"> 4.9. For patients who fail treatment with MPA or CY either because of lack of effect (as defined in 3.2) or due to adverse events, we recommend that the treatment is switched from MPA to CY, or CY to MPA, or rituximab be given</td><td rowspan="1" colspan="1">9.2 (1.0)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td colspan="3" rowspan="1">5. Adjunct treatment in patients with LN</td></tr><tr><td rowspan="1" colspan="1"> 5.1. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers are indicated for patients with proteinuria (UPCR >50 mg/mmol) or hypertension</td><td rowspan="1" colspan="1">9.7 (0.8)</td><td rowspan="1" colspan="1">10 (0)</td></tr><tr><td rowspan="1" colspan="1"> 5.2. Cholesterol lowering with statins is indicated for persistent dyslipidaemia (target low-density lipoprotein (LDL)-cholesterol 2.58 mmol/litre (100 mg/dl))</td><td rowspan="1" colspan="1">9.2 (1.3)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td rowspan="1" colspan="1"> 5.3. Hydroxychloroquine is recommended to improve outcomes by reducing renal flares and limiting the accrual of renal and cardiovascular damage</td><td rowspan="1" colspan="1">9.3 (1.7)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td rowspan="1" colspan="1"> 5.4. Acetyl-salicylic acid in patients with anti-phospholipid antibodies, calcium and vitamin D supplementation, and immunisations with non-live vaccines may reduce treatment or disease-related comorbidities and should be considered</td><td rowspan="1" colspan="1">9.3 (1.3)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td rowspan="1" colspan="1"> 5.5. Consider anticoagulant treatment in nephrotic syndrome with serum albumin <20 g/litre, especially if persistent or in the presence of anti-phospholipid antibodies</td><td rowspan="1" colspan="1">9.2 (1.1)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td colspan="3" rowspan="1">6. Monitoring and prognosis of LN</td></tr><tr><td rowspan="1" colspan="1"> 6.1. Active LN should be regularly monitored by determining at each visit body weight, blood pressure, serum creatinine and eGFR, serum albumin, proteinuria, urinary sediment (microscopic evaluation), serum C3 and C4, serum anti-dsDNA antibody levels and complete blood cell count. Anti-phospholipid antibodies and lipid profile should be measured at baseline and monitored intermittently.</td><td rowspan="1" colspan="1">9.3 (0.9)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td rowspan="1" colspan="1"> 6.2. Changes in serum creatinine (eGFR), proteinuria, haemoglobin levels and blood pressure are predictors of long-term outcome in LN</td><td rowspan="1" colspan="1">9.2 (1.2)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td rowspan="1" colspan="1"> 6.3. Visits should be scheduled every 2–4 weeks for the first 2–4 months after diagnosis or flare, and then according to the response to treatment. Monitoring for renal and extra-renal disease activity should be lifelong at least every 3–6 months.</td><td rowspan="1" colspan="1">9.1 (1.4)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td rowspan="1" colspan="1"> 6.4. Repeat renal biopsy may be used in selected cases, such as worsening or refractoriness to immunosuppressive or biological treatment (failure to decrease proteinuria by ≥50%, persistent proteinuria beyond 1 year and/or worsening of GFR), or at relapse, to demonstrate change or progression in histological class, change in biopsy chronicity and activity indices, to provide prognostic information, and detect other pathologies</td><td rowspan="1" colspan="1">9.2 (1.4)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td colspan="3" rowspan="1">7. Management of end-stage renal disease (ESRD) in LN</td></tr><tr><td rowspan="1" colspan="1"> 7.1. All methods of renal replacement treatment can be used in patients with lupus, but there may be increased risk of infections in patients on peritoneal dialysis still on immunosuppressive agents and vascular access thrombosis in patients with anti-phospholipid antibodies</td><td rowspan="1" colspan="1">9.5 (0.8)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td rowspan="1" colspan="1"> 7.2. Transplantation should be performed when lupus activity has been absent, or at a low level, for at least
3– 6 months, with superior results obtained with living donor and pre-emptive transplantation. Anti-phospholipid antibodies should be sought during transplant preparation because they are associated with an increased risk of vascular events in the transplanted kidney.</td><td rowspan="1" colspan="1">9.4 (0.9)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td colspan="3" rowspan="1">8. Anti-phospholipid syndrome-associated nephropathy in SLE</td></tr><tr><td rowspan="1" colspan="1"> In patients with lupus and anti-phospholipid syndrome (APS)-associated nephropathy (APSN), hydroxychloroquine and/or antiplatelet/anticoagulant treatment should be considered</td><td rowspan="1" colspan="1">9.0 (1.4)</td><td rowspan="1" colspan="1">9 (2)</td></tr><tr><td colspan="3" rowspan="1">9. LN and pregnancy</td></tr><tr><td rowspan="1" colspan="1"> 9.1. Pregnancy may be planned in stable patients with inactive lupus and UPCR <50 mg/mmol, for the preceding 6 months, with GFR that should preferably be >50 ml/min. Acceptable medications include hydroxychloroquine, and where needed, low dose prednisone, azathioprine and/or calcineurin inhibitors. The intensity of treatment should not be reduced in anticipation of pregnancy. During pregnancy, acetylsalicylic acid should be considered to reduce the risk of pre-eclampsia. Patients should be assessed at least every 4 weeks, preferably by a specialist physician and obstetrician.</td><td rowspan="1" colspan="1">9.3 (1.0)</td><td rowspan="1" colspan="1">10 (1)</td></tr><tr><td rowspan="1" colspan="1"> 9.2. Flare of LN during pregnancy can be treated with acceptable medications stated above depending on severity of flare</td><td rowspan="1" colspan="1">9.0 (1.5)</td><td rowspan="1" colspan="1">10 (2)</td></tr><tr><td colspan="3" rowspan="1">10. Management of paediatric LN</td></tr><tr><td rowspan="1" colspan="1"> Compared to adult-onset disease, LN in children is more severe with increased damage accrual and more common at presentation but the diagnosis, management and monitoring is similar to that of adults. A coordinated transition programme to adult specialists is important in assessing concordance to treatments and optimising long-term outcomes.</td><td rowspan="1" colspan="1">9.6 (0.7)</td><td rowspan="1" colspan="1">10 (1)</td></tr></tbody></table><table-wrap-foot><fn><p>*Numbers are mean (SD) and median (IQR) agreement level among experts. A score of 10 represents the highest level of agreement.</p></fn><fn><p>GFR, glomerular filtration rate; UPCR, urine protein:creatinine ratio.</p></fn></table-wrap-foot></table-wrap><table-wrap id="annrheumdis2012201940TB2" position="float"><label>Table 2</label><caption><p>Category of evidence and strength of statements*</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col></colgroup><thead><tr><th rowspan="1" colspan="1">Statement/item</th><th rowspan="1" colspan="1">Level of evidence</th><th rowspan="1" colspan="1">Strength of statement</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">1. Indications for first renal biopsy</td></tr><tr><td rowspan="1" colspan="1"> Diagnostic value of urinary findings (proteinuria ≥0.5 g/24 h especially with glomerular haematuria and/or cellular casts)</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Clinical, serological or laboratory tests correlate modestly with renal biopsy findings</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td colspan="3" rowspan="1">2. Pathological assessment of kidney biopsy</td></tr><tr><td rowspan="1" colspan="1"> International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification system preferred</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Prognostic value of glomerular changes</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">A</td></tr><tr><td rowspan="1" colspan="1"> Prognostic value of activity and chronicity indices</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">A</td></tr><tr><td rowspan="1" colspan="1"> Prognostic value of tubulointerstitial lesions</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Prognostic value of vascular lesions associated with anti-phospholipid antibodies</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">C</td></tr><tr><td colspan="3" rowspan="1">3. Indications for immunosuppressive treatment and treatment strategy</td></tr><tr><td rowspan="1" colspan="1"> Diagnostic renal biopsy required</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Immunosuppression for class III<sub>A</sub> or III<sub>A/C</sub> (±V) and IV<sub>A</sub> or IV<sub>A/C</sub> (±V) nephritis</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">A</td></tr><tr><td rowspan="1" colspan="1"> Immunosuppression for class V nephritis if proteinuria >1 g/24 h</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Target: preservation of renal function, prevention of disease flares, avoidance of treatment-related harms and improved quality of life and survival</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Prognostic value of complete renal response (UPCR <50 mg/mmol and normal or near-normal GFR)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Prognostic value of partial renal response (≥50% reduction in proteinuria and normal or near-normal GFR)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">B</td></tr><tr><td colspan="3" rowspan="1">4. Treatment of adult lupus nephritis (LN)</td></tr><tr><td colspan="3" rowspan="1"> Class III<sub>A</sub> or <sub>A/C</sub> (±V) and class IV<sub>A</sub> or <sub>A/C</sub> (±V): glucocorticoids plus</td></tr><tr><td rowspan="1" colspan="1"> Mycophenolic acid (MPA)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">A†</td></tr><tr><td rowspan="1" colspan="1"> Low-dose intravenous cyclophosphamide (CY)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">B</td></tr><tr><td colspan="3" rowspan="1"> If adverse clinical/histological prognostic factors are present: glucocorticoids plus</td></tr><tr><td rowspan="1" colspan="1"> MPA</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Low-dose intravenous CY</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> High-dose intravenous CY</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">A</td></tr><tr><td rowspan="1" colspan="1"> Oral CY</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">B</td></tr><tr><td colspan="3" rowspan="1"> Use of glucocorticoids</td></tr><tr><td rowspan="1" colspan="1"> Three consecutive pulses of intravenous methylprednisolone 500–750 mg</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Then, oral prednisolone 0.5 mg/kg/day for 4 weeks with subsequent tapering</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td colspan="3" rowspan="1"> Pure class V nephritis with nephrotic-range proteinuria: glucocorticoids plus</td></tr><tr><td rowspan="1" colspan="1"> MPA</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> High-dose intravenous CY</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">A</td></tr><tr><td rowspan="1" colspan="1"> Ciclosporin (increased rates of relapse of nephrotic syndrome)</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">A</td></tr><tr><td rowspan="1" colspan="1"> Tacrolimus</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Rituximab</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">C</td></tr><tr><td colspan="3" rowspan="1"> Azathioprine (AZA) use in LN</td></tr><tr><td rowspan="1" colspan="1"> In selected patients without adverse clinical or histological prognostic factors</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Class III–IV nephritis</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Class V nephritis (non-nephrotic-range proteinuria)</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> When MPA or CY are contraindicated, not tolerated, or unavailable</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Associated with higher relapse risk</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td colspan="3" rowspan="1"> Subsequent immunosuppression in class III–IV or V nephritis</td></tr><tr><td rowspan="1" colspan="1"> MPA or AZA, in combination with low-dose glucocorticoids</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">A</td></tr><tr><td rowspan="1" colspan="1"> Successful induction with MPA followed by continuing MPA</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> AZA preferred if pregnancy planned</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Duration of immunosuppressive treatment: at least 3 years</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Gradual drug withdrawal, glucocorticoids first, can then be attempted</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Calcineurin inhibitors can be considered in pure class V nephritis</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">C</td></tr><tr><td colspan="3" rowspan="1">Failure to treatment with MPA or CY</td></tr><tr><td rowspan="1" colspan="1"> Switch from MPA to CY</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Switch from CY to MPA</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Add or switch to rituximab</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">C</td></tr><tr><td colspan="3" rowspan="1">5. Adjunct treatment</td></tr><tr><td rowspan="1" colspan="1"> Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for proteinuria or hypertension</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Cholesterol lowering with statins for persistent dyslipidaemia</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Hydroxychloroquine</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Acetyl-salicylic acid in patients with anti-phospholipid antibodies</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Calcium and vitamin D supplementation</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Immunisations with non-live vaccines</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Anticoagulant treatment in nephrotic syndrome with serum albumin <20 g/litre</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td colspan="3" rowspan="1">Monitoring and prognosis of LN</td></tr><tr><td rowspan="1" colspan="1"> Serum creatinine and GFR, proteinuria, and urinary microscopy to define activity</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Body weight and blood pressure measurement to assess activity and response to treatment</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Diagnostic utility of</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Serum C3</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Serum C4</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Serum anti-dsDNA</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Complete blood cell count</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Serum albumin</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">C</td></tr><tr><td colspan="3" rowspan="1"> Prognostic value of</td></tr><tr><td rowspan="1" colspan="1"> Anti-phospholipid antibodies</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Serum lipids</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td colspan="3" rowspan="1"> Prognostic value of serial changes in</td></tr><tr><td rowspan="1" colspan="1"> Serum creatinine/GFR</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">A</td></tr><tr><td rowspan="1" colspan="1"> Proteinuria</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">A</td></tr><tr><td rowspan="1" colspan="1"> Haemoglobin</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Blood pressure</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">A</td></tr><tr><td colspan="3" rowspan="1"> Frequency of monitoring</td></tr><tr><td rowspan="1" colspan="1"> Every 2–4 weeks for the first 2–4 months after diagnosis or flare</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Lifelong at least 3–6 monthly</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td colspan="3" rowspan="1"> Repeat renal biopsy</td></tr><tr><td rowspan="1" colspan="1"> Useful in worsening or refractory disease or at relapse</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Strong prognostic value of renal biopsy findings</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td colspan="3" rowspan="1">7. End-stage renal disease (ESRD) in systemic lupus erythematosus (SLE)</td></tr><tr><td rowspan="1" colspan="1"> All methods of renal replacement treatment are safe</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Increased risk for infections in patients on peritoneal dialysis</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Increased risk for vascular access thrombosis with anti-phospholipid antibodies</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">C</td></tr><tr><td colspan="3" rowspan="1"> Transplantation.</td></tr><tr><td rowspan="1" colspan="1"> Better outcome when lupus activity is absent or at a low level for 3–6 months</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Better outcome with living versus cadaveric donor</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Better outcome with pre-emptive transplantation</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Increased risk for vascular events in patients with anti-phospholipid antibodies</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td colspan="3" rowspan="1">8. Treatment of anti-phospholipid syndrome (APS)-associated nephropathy (APSN)</td></tr><tr><td rowspan="1" colspan="1"> Hydroxychloroquine</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Antiplatelet/anticoagulation treatment</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td colspan="3" rowspan="1">9. LN and pregnancy</td></tr><tr><td rowspan="1" colspan="1"> Safe in inactive SLE with UPCR <50 mg/mmol for the preceding 6 months</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> GFR preferably above 50 ml/min</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td colspan="3" rowspan="1"> Safety and efficacy of the following medications</td></tr><tr><td rowspan="1" colspan="1"> Hydroxychloroquine</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Low-dose prednisone</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Azathioprine</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Calcineurin inhibitors</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Intensity of treatment should not be reduced in anticipation of pregnancy</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Acetylsalicylic acid to reduce the risk of pre-eclampsia</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Assessment every 4 weeks, preferably by a specialist physician and obstetrician</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Flare of nephritis can be treated with same acceptable medications but also with calcineurin inhibitors, intravenous immunoglobulin, immunoadsorption and plasma exchange</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr><tr><td colspan="3" rowspan="1">10. Paediatric LN</td></tr><tr><td rowspan="1" colspan="1"> More common at presentation compared to adult-onset SLE</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">A</td></tr><tr><td rowspan="1" colspan="1"> More severe with increased damage accrual compared to adult-onset disease</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1"> Similar monitoring with adults</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Similar treatment with adults</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">C</td></tr><tr><td rowspan="1" colspan="1"> Importance of coordinated transition programme to adult specialists</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">C</td></tr></tbody></table><table-wrap-foot><fn><p>*Quality of evidence was graded 1–4 and the strength of statements was graded A–C (refer to <ext-link ext-link-type="uri" xlink:href="http://.oxfordjournals.org/lookup/suppl/doi:10.1093//annrheumdis-2012-201940/-/DC1">web-only appendix table 1</ext-link> for details).</p></fn><fn><p>†MPA refers to either mycophenolate mofetil (MMF) or enteric-coated MPA sodium at equivalent dose based on evidence for comparable efficacy of the two regimens. MMF has been used in most controlled trials in LN.</p></fn><fn><p>dsDNA, double-stranded DNA; GFR, glomerular filtration rate; UPCR, urine protein:creatinine ratio.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3"><title>Results and discussion</title><sec id="s3a"><title>Indications for first renal biopsy in SLE</title><p>Because of the potentially aggressive nature of LN, the thresholds for performing a renal biopsy should be low. Any sign of renal involvement—in particular, reproducible proteinuria ≥0.5 g/24 h especially with glomerular haematuria and/or cellular casts—can be an indication for biopsy. Clinical, serological or laboratory tests cannot accurately predict histological findings<italic>.</italic> Although clinically relevant biopsy findings are more common in the presence of significant proteinuria, a biopsy may also be considered in cases of persisting isolated glomerular haematuria, isolated leucocyturia (after other causes, such as infection or drugs are excluded),<xref ref-type="bibr" rid="R3">3</xref><xref ref-type="bibr" rid="R4">4</xref> and the rare occurrence of unexplained renal insufficiency with normal urinary findings. Lower glomerular filtration rate (GFR) is associated with chronic histological lesions and faster rate of decline in GFR.<xref ref-type="bibr" rid="R5 R6 R7 R8 R9">5–9</xref> Methods for estimating GFR such as the Cockcroft–Gault and the Modification of Diet in Renal Disease equations in adults or the Schwartz formula in children, although not fully validated in SLE,<xref ref-type="bibr" rid="R10">10</xref><xref ref-type="bibr" rid="R11">11</xref> are acceptable in clinical practice. For GFR <30 ml/min the decision for biopsy should be based on normal kidney size (>9 cm length in adults) and/or evidence of renal disease activity, in particular proteinuria and active urinary sediment (dysmorphic red blood cells (glomerular haematuria), white blood cells and/or cellular casts). Biopsy should be performed within the first month after disease onset, preferably before the institution of immunosuppressive treatment, unless contraindicated.<xref ref-type="bibr" rid="R12 R13 R14">12–14</xref> Treatment with high-dose glucocorticoids should not be delayed if a renal biopsy cannot be readily performed.</p></sec><sec id="s3b"><title>Pathological assessment of renal biopsy</title><p>We recommend using the International Society of Nephrology/Renal Pathology Society 2003 classification system<xref ref-type="bibr" rid="R15 R16 R17">15–17</xref> with assessment of active and chronic glomerular and tubulointerstitial changes,<xref ref-type="bibr" rid="R18 R19 R20 R21">18–21</xref> and of vascular lesions associated with anti-phospholipid antibodies/syndrome.<xref ref-type="bibr" rid="R22">22</xref><xref ref-type="bibr" rid="R23">23</xref> An adequate sample of ≥8 glomeruli should be examined under light microscopy<xref ref-type="bibr" rid="R15">15</xref><xref ref-type="bibr" rid="R24">24</xref> with haematoxylin and eosin, periodic acid-Schiff, Masson's trichrome and silver stain. Immunofluorescence or immunohistochemistry for immunoglobulin and complement deposits (IgG, IgA, IgM, C3, C1q, κ and λ light chains) is recommended.<xref ref-type="bibr" rid="R12">12</xref><xref ref-type="bibr" rid="R21">21</xref><xref ref-type="bibr" rid="R25">25</xref><xref ref-type="bibr" rid="R26">26</xref> Electron microscopy facilitates the recognition of proliferative and membranous lesions and should be performed if possible.<xref ref-type="bibr" rid="R19">19</xref><xref ref-type="bibr" rid="R27 R28 R29">27–29</xref></p></sec><sec id="s3c"><title>Indications and goals of immunosuppressive treatment in LN</title><p>Ultimate goals of treatment are long-term preservation of renal function, prevention of flares, avoidance of treatment-related harms, and improved quality of life and survival. Treatment must be based on a shared decision between patient and doctor. Immunosuppressive treatment is generally not indicated in classes I and VI LN, unless necessitated by extra-renal lupus activity.<xref ref-type="bibr" rid="R30 R31 R32">30–32</xref></p><p>Treatment should aim for complete renal response, defined as urine protein:creatinine ratio (UPCR) <50 mg/mmol (roughly equivalent to proteinuria <0.5 g/24 h) and normal or near-normal (within 10% of normal GFR if previously abnormal) GFR. Partial renal response, defined as ≥50% reduction in proteinuria to subnephrotic levels and normal or near-normal GFR, should be achieved preferably by 6 months and no later than 12 months following treatment initiation.<xref ref-type="bibr" rid="R9">9</xref><xref ref-type="bibr" rid="R33 R34 R35">33–35</xref> Improvement includes any reduction in proteinuria and normalisation or stabilisation of GFR. Although partial response carries worse prognosis than complete response,<xref ref-type="bibr" rid="R34">34</xref><xref ref-type="bibr" rid="R36">36</xref><xref ref-type="bibr" rid="R37">37</xref> it may be an acceptable outcome when all treatments have been exhausted or cannot be used due to high individual risks for toxicity. Following response, patients may experience nephritic or proteinuric flares, the former having more adverse impact on renal outcomes.<xref ref-type="bibr" rid="R34">34</xref><xref ref-type="bibr" rid="R37 R38 R39">37–39</xref> Nephritic flares include reproducible increase of serum creatinine by ≥30% (or, decrease in GFR by ≥10%) and active urine sediment with increase in glomerular haematuria by ≥10 red blood cells per high power field, irrespective of changes in proteinuria; proteinuric flares include reproducible doubling of UPCR to >100 mg/mmol after complete response or reproducible doubling of UPCR to >200 mg/mmol after partial response.<xref ref-type="bibr" rid="R34">34</xref><xref ref-type="bibr" rid="R37">37</xref><xref ref-type="bibr" rid="R38">38</xref></p></sec><sec id="s3d"><title>Treatment of adult LN</title><sec id="s3d1"><title>Initial treatment</title><p>Patients with LN should be managed, if possible, in experienced centres.<xref ref-type="bibr" rid="R40">40</xref> Early trials of immunosuppressive agents have highlighted the importance of long-term (beyond 5 years) follow-up in demonstrating differences in ‘hard’ outcomes such as doubling of serum creatinine, end-stage renal disease (ESRD) and death.<xref ref-type="bibr" rid="R41 R42 R43">41–43</xref> Such outcomes, however, are not frequent and may occur late in the course of LN. Intermediate outcome measures, such as renal response and flares, occurring in the majority of patients within the first 2 years after treatment initiation, correlate with hard outcomes in studies with long-term follow-up and are commonly used as endpoints in trials.<xref ref-type="bibr" rid="R9">9</xref><xref ref-type="bibr" rid="R33 R34 R35">33–35</xref><xref ref-type="bibr" rid="R37 R38 R39">37–39</xref><xref ref-type="bibr" rid="R44">44</xref> Correlation does not guarantee surrogacy of these outcomes for all patients, some of whom may still have hard outcomes diverging from their intermediate outcomes.</p><p>To date, long-term data are not available for MPA (<xref ref-type="boxed-text" rid="bx1">box 1</xref>). Nonetheless, the publication of the Aspreva Lupus Management Study (ALMS) trial,<xref ref-type="bibr" rid="R45">45</xref> the largest trial in LN showing comparable response rates between MPA (target mycophenolate mofetil (MMF) dose 3 g/day) and intravenous cyclophosphamide (CY) (monthly pulses 0.5–1 g/m<sup>2</sup>), both administered for 6 months, together with the ease of administration and the more favourable gonadal toxicity profile of the former,<xref ref-type="bibr" rid="R46 R47 R48">46–48</xref> formed the basis for recommending MPA as initial treatment for most cases of class III–IV LN. Evidence from transplantation medicine<xref ref-type="bibr" rid="R49">49</xref><xref ref-type="bibr" rid="R50">50</xref> and a single randomised controlled trial (RCT) in LN<xref ref-type="bibr" rid="R51">51</xref> suggests that MMF and enteric-coated mycophenolic acid sodium (eMPA) are likely to be equally efficacious. To this end, and while awaiting further validation, the Committee felt that either MPA formulation can be used in treatment of LN, with 720 mg dose eMPA roughly equivalent to 1 g dose of MMF. We also recommend low-dose intravenous CY (total dose 3 g over 3 months) in combination with glucocorticoids (0.5 mg/kg/day) as initial treatment of class III–IV (±V) LN in Caucasians based on better efficacy/toxicity ratio than high-dose intravenous CY.<xref ref-type="bibr" rid="R44">44</xref><xref ref-type="bibr" rid="R52">52</xref><boxed-text id="bx1" position="float"><label>Box 1</label><caption><title>Research agenda</title></caption><list list-type="bullet"><list-item><p>Special training sessions for renal pathologists to improve the interpretation of renal biopsy findings in lupus nephritis (LN) and enhance interobserver agreement</p></list-item><list-item><p>Development and validation of biomarkers which will better reflect kidney biopsy findings and renal disease activity and severity</p></list-item><list-item><p>Long-term (beyond 5 years) efficacy and safety data for mycophenolic acid</p></list-item><list-item><p>Provide data to guide duration of immunosuppressive treatment beyond 3 years</p></list-item><list-item><p>Define the role of adding calcineurin inhibitors, rituximab or belimumab to standard immunosuppressive treatment in cases with residual renal disease</p></list-item><list-item><p>Need for more data on switching regimens in cases of treatment failure</p></list-item><list-item><p>Larger studies with extended follow-up are needed to assess the prognostic significance of anti-phospholipid syndrome (APS)-associated nephropathy (APSN) and coexistence of anti-phospholipid antibodies in LN</p></list-item><list-item><p>Need for controlled trials to assess the role of antiplatelet/anticoagulant regimes in APSN</p></list-item><list-item><p>Need for randomised controlled trials (RCTs) in paediatric LN and the need to have very long follow-up (beyond 10–15 years) to fully assess the impact of the various treatment strategies and modalities in children</p></list-item></list></boxed-text></p><p>A single RCT in patients with pure class V LN demonstrated that the combination of glucocorticoids with intravenous CY (6 bimonthly pulses 0.5–1 g/m<sup>2</sup>) was more efficacious than glucocorticoids alone; the combination of glucocorticoids with ciclosporin was also efficacious but was associated with significantly more relapses of nephrotic syndrome than CY.<xref ref-type="bibr" rid="R53">53</xref> Moreover, combined analysis of two other RCTs in the subgroup of patients with pure class V LN showed a comparable antiproteinuric effect of MPA versus high-dose intravenous CY.<xref ref-type="bibr" rid="R54">54</xref> By extrapolation from these studies, and based on the more favourable gonadal toxicity profile of MPA compared to CY, we recommend MPA as initial treatment for most cases of class V LN and nephrotic-range proteinuria. The low-dose CY regimen has not been tested in pure class V LN.</p><p>Subgroup analysis suggests that MPA may have greater efficacy in patients of African descent;<xref ref-type="bibr" rid="R45">45</xref><xref ref-type="bibr" rid="R55">55</xref> further confirmation is needed before issuing a recommendation favouring MPA in these patients. Post hoc analysis in 32 patients in ALMS with baseline GFR<30 ml/min/1.73 m<sup>2</sup>,<xref ref-type="bibr" rid="R45">45</xref> and evidence from 2 controlled studies in severe histological forms of LN,<xref ref-type="bibr" rid="R56">56</xref><xref ref-type="bibr" rid="R57">57</xref> support the use of MPA in patients with impaired renal function or crescents. Only high-dose intravenous CY has demonstrated efficacy in a RCT specifically designed to include severe nephritic cases with GFR 25–80 ml/min or with crescents/necrosis in >25% of glomeruli.<xref ref-type="bibr" rid="R58">58</xref> Data from a RCT<xref ref-type="bibr" rid="R59">59</xref> and the 10-year follow-up<xref ref-type="bibr" rid="R60">60</xref> suggest that azathioprine can be used in class III–IV LN albeit at an increased risk for renal relapse (HR 4.5), thus the committee recommends it for milder cases (preserved renal function and no adverse histological findings).</p><p>Intravenous methylprednisolone (MP) pulses are recommended as part of the initial treatment regimen by extrapolation from controlled studies,<xref ref-type="bibr" rid="R43">43</xref><xref ref-type="bibr" rid="R52">52</xref><xref ref-type="bibr" rid="R61">61</xref><xref ref-type="bibr" rid="R62">62</xref> to decrease cumulative glucocorticoid dose and associated harms. Higher initial glucocorticoid dose (oral prednisone 0.7–1 mg/kg/day) may be used in severe renal or extra-renal lupus, or when intravenous MP treatment is not feasible. Clinical experience suggests that a further course of three intravenous MP pulses can be considered in patients failing to improve within the first 3 months.</p><p>For class II LN with proteinuria >1 g/24 h despite renin-angiotensin-aldosterone system (RAAS) blockade, especially in the presence of glomerular haematuria, we recommend low-to-moderate doses of glucocorticoids (prednisone 0.25–0.5 mg/kg/day) alone or in combination with azathioprine (1–2 mg/kg/day), if needed, as steroid-sparing agent. Glucocorticoids alone or in combination with immunosuppressive agents may also be considered in cases of class I LN with podocytopathy on the electron microscopy (minimal change disease)<xref ref-type="bibr" rid="R63">63</xref><xref ref-type="bibr" rid="R64">64</xref> or interstitial nephritis.<xref ref-type="bibr" rid="R65">65</xref><xref ref-type="bibr" rid="R66">66</xref></p></sec><sec id="s3d2"><title>Subsequent treatment</title><p>For patients improving after initial treatment, we recommend subsequent immunosuppression to consolidate renal response and prevent flares. Although among patients from European ancestries azathioprine and MPA were equivalent after initial treatment with low-dose intravenous CY,<xref ref-type="bibr" rid="R67">67</xref> a larger RCT suggested a difference between the two drugs in favour of MPA after initial response to either MPA or intravenous CY (monthly pulses 0.5–1 g/m<sup>2</sup>).<xref ref-type="bibr" rid="R68">68</xref> In this trial, sequential use of azathioprine after MPA resulted in more treatment failures as compared to MPA followed by MPA. The committee therefore recommends continuation of MPA if the drug was successful as initial treatment. Calcineurin inhibitors can be considered in selected cases with preserved renal function based on evidence from RCTs.<xref ref-type="bibr" rid="R69 R70 R71">69–71</xref> Intravenous CY, pulsed every 3 months, may be used in selected cases<xref ref-type="bibr" rid="R43">43</xref><xref ref-type="bibr" rid="R58">58</xref><xref ref-type="bibr" rid="R72">72</xref> but exposure to CY should be minimised, especially in women at risk for amenorrhoea and infertility<xref ref-type="bibr" rid="R73">73</xref> or men planning to father children.</p><p>There is no data to guide duration of treatment beyond 3 years;<xref ref-type="bibr" rid="R67">67</xref><xref ref-type="bibr" rid="R68">68</xref> continuing treatment for longer time periods should be individualised with an effort first to withdraw glucocorticoids before immunosuppressive agents. Gradual drug dosage titration may be attempted to ensure the best possible efficacy/toxicity ratio. MPA dose often needs titration to reduce toxicity (doses 1–2 g/day can be effective for long-term treatment). Monitoring MPA blood levels to minimise harm and increase efficacy is under investigation<xref ref-type="bibr" rid="R74 R75 R76">74–76</xref> but it should be considered in cases with GFR <30 ml/min.</p></sec><sec id="s3d3"><title>Refractory disease</title><p>Complete renal response can take up to 2 years to reach with <30% to 40% of patients achieving this outcome within the first 6 months of treatment.<xref ref-type="bibr" rid="R48">48</xref><xref ref-type="bibr" rid="R59">59</xref> Switching to an alternative agent is recommended for patients who fail to improve within 3–4 months, or do not achieve partial response after 6–12 months, or complete response after 2 years of treatment. For patients not responding to MPA or CY, evidence from uncontrolled studies suggests that treatment may be switched from MPA to CY, from CY to MPA,<xref ref-type="bibr" rid="R77">77</xref><xref ref-type="bibr" rid="R78">78</xref> or that rituximab (anti-CD20 mAb) may be given either as add-on treatment or as monotherapy.<xref ref-type="bibr" rid="R79">79</xref><xref ref-type="bibr" rid="R80">80</xref> Additional options include calcineurin inhibitors (ciclosporin A, tacrolimus),<xref ref-type="bibr" rid="R81 R82 R83">81–83</xref> intravenous immunoglobulin,<xref ref-type="bibr" rid="R84">84</xref> plasma exchange for rapidly progressive glomerulonephritis,<xref ref-type="bibr" rid="R49">49</xref><xref ref-type="bibr" rid="R85">85</xref> or immunoadsorption for patients who have failed or cannot tolerate other treatments.<xref ref-type="bibr" rid="R86">86</xref><xref ref-type="bibr" rid="R87">87</xref> Data on leflunomide are limited.<xref ref-type="bibr" rid="R88">88</xref></p></sec></sec><sec id="s3e"><title>Adjunctive treatment in patients with LN</title><p>We recommend control of cardiovascular disease risk factors in a manner similar to patients who do not have SLE with chronic kidney disease, although benefit has not been demonstrated specifically in SLE.<xref ref-type="bibr" rid="R89">89</xref> Complications of chronic renal insufficiency (anaemia, cardiovascular disease, metabolic bone disease) should also be managed as in patients who do not have SLE. RAAS blockers are recommended as preferred treatment in all patients who are not pregnant with significant proteinuria or hypertension, based on: (a) evidence for their antihypertensive, antiproteinuric and renoprotective effect,<xref ref-type="bibr" rid="R90 R91 R92">90–92</xref> and, (b) lack of data on the comparative efficacy of other classes of antihypertensive agents in LN. Their dose is titrated for maximum antiproteinuric effect while monitoring blood pressure (target level <130/80 mm Hg), serum potassium and GFR levels. Epidemiological studies<xref ref-type="bibr" rid="R93">93</xref><xref ref-type="bibr" rid="R94">94</xref> and the follow-up of a controlled trial<xref ref-type="bibr" rid="R95">95</xref> demonstrate that hydroxychloroquine use is associated with higher rates of renal response, fewer renal relapses and reduced accrual of renal damage. Hydroxychloroquine (6.5 mg/kg/day or 400 mg/day, whichever is lower) is generally safe in patients with normal baseline ophthalmological examination; dose adjustments may be necessary in patients with GFR <30 ml/min. Annual ophthalmological screening begins after 5 years of treatment or sooner if there are risk factors for retinal damage.<xref ref-type="bibr" rid="R96">96</xref> Patients should also be immunised with non-live vaccines according to the EULAR recommendations.<xref ref-type="bibr" rid="R97">97</xref><xref ref-type="bibr" rid="R98">98</xref></p></sec><sec id="s3f"><title>Monitoring and prognosis of LN</title><p>Patients should be monitored regularly according to EULAR recommendations,<xref ref-type="bibr" rid="R99">99</xref> including annual examination of cervicovaginal smear in women<xref ref-type="bibr" rid="R100">100</xref><xref ref-type="bibr" rid="R101">101</xref> and measurement of serum immunoglobulins at baseline and then annually in patients who receive immunosuppressive treatment to assess risk of infection. Monitoring of body weight, blood pressure, serum creatinine and estimated GFR, serum albumin, proteinuria, urinary sediment (microscopic evaluation), serum C3/C4, serum anti-dsDNA antibody levels and complete blood cell count are used to define activity and evaluate response to treatment although their individual predictive value for hard outcomes at particular time points is modest.</p><p>Spot UPCR measured on first morning void urine sample is a valid and conveniently repeatable measure for measuring proteinuria in children and monitoring within-patient changes in adults.<xref ref-type="bibr" rid="R102 R103 R104">102–104</xref> Timed (12 h or 24 h) urine collections may also be considered at baseline and when major therapeutic changes are considered. Reappearance of urine cellular casts has >80% sensitivity and specificity for renal flares.<xref ref-type="bibr" rid="R105">105</xref></p><p>Although serum C3 has generally higher sensitivity than serum C4 (72% to 85% vs 28% to 74%), both tests have modest specificity for active LN.<xref ref-type="bibr" rid="R106">106</xref><xref ref-type="bibr" rid="R107">107</xref> The diagnostic accuracy of serum anti-dsDNA is also modest with positive and negative likelihood ratios ranging from 1.5–4.8 and 0.3–0.8, respectively. Farr and ELISA methods are both acceptable, although the former yields higher sensitivity and specificity rates.<xref ref-type="bibr" rid="R106">106</xref><xref ref-type="bibr" rid="R108 R109 R110">108–110</xref> Anti-C1q<xref ref-type="bibr" rid="R106">106</xref><xref ref-type="bibr" rid="R111">111</xref> and anti-nucleosome<xref ref-type="bibr" rid="R112 R113 R114">112–114</xref> antibodies have higher sensitivity and specificity for active nephritis but further standardisation and validation are required. Changes in serological tests are more important predictors of concurrent or impending LN flare than their absolute levels but should be repeated no more than monthly. In the absence of proteinuria, active serology (decreasing C3/C4 and/or increasing anti-dsDNA) and/or urine sediment is not an indication for pre-emptive treatment but dictates closer monitoring of patients. Repeat renal biopsy provides additional prognostic information<xref ref-type="bibr" rid="R115 R116 R117 R118">115–118</xref> and can assist therapeutic decisions in patients with relapse of nephritis after complete renal response, or with refractory disease. It can also be used in the context of a clinical trial to monitor treatment efficacy and changes in chronicity scores.<xref ref-type="bibr" rid="R8">8</xref><xref ref-type="bibr" rid="R119">119</xref></p></sec><sec id="s3g"><title>Management of ESRD in LN</title><p>Despite immunosuppressive treatment, 10% to 30% of patients with LN will progress to ESRD within 15 years of diagnosis. Infections (including peritonitis) may occur in patients with active disease still on immunosuppressive treatment, and contribute to morbidity and mortality.<xref ref-type="bibr" rid="R120 R121 R122 R123">120–123</xref> Although clinical and serological activity tend to subside in most patients with ESRD on dialysis,<xref ref-type="bibr" rid="R120">120</xref><xref ref-type="bibr" rid="R124 R125 R126">124–126</xref> flares of renal or extra-renal lupus can occur.<xref ref-type="bibr" rid="R127 R128 R129 R130">127–130</xref></p><p>Comparative studies<xref ref-type="bibr" rid="R131">131</xref><xref ref-type="bibr" rid="R132">132</xref> and cases series<xref ref-type="bibr" rid="R133">133</xref><xref ref-type="bibr" rid="R134">134</xref> support that patients with SLE are good candidates for renal transplantation performed when clinical (and ideally, serological) lupus activity is absent, or at a low level, for at least 3–6 months<xref ref-type="bibr" rid="R135">135</xref>; best results are obtained with living donor<xref ref-type="bibr" rid="R136 R137 R138">136–138</xref> and pre-emptive transplantation.<xref ref-type="bibr" rid="R139">139</xref> Patients with moderate to high titres of anti-phospholipid antibodies are at increased risk for thrombotic complications and may receive anticoagulants perioperatively.<xref ref-type="bibr" rid="R140 R141 R142 R143">140–143</xref> Post-transplantation recurrent LN, although difficult to treat, is a rare cause of renal allograft loss.<xref ref-type="bibr" rid="R136">136</xref><xref ref-type="bibr" rid="R144">144</xref><xref ref-type="bibr" rid="R145">145</xref></p></sec><sec id="s3h"><title>Anti-phospholipid syndrome (APS)-associated nephropathy (APSN) in SLE</title><p>Anti-phospholipid antibodies (anti-cardiolipin antibodies, anti-β2-glycoprotein I antibodies, lupus anticoagulant) may be associated with a distinct type of vascular nephropathy (APSN) with adverse prognostic factors such as hypertension, impaired renal function and interstitial fibrosis.<xref ref-type="bibr" rid="R146 R147 R148 R149">146–149</xref> Histological lesions of APSN are present in 20% to 30% of patients with SLE<xref ref-type="bibr" rid="R146">146</xref><xref ref-type="bibr" rid="R150">150</xref> and include thrombotic microangiopathy and chronic lesions such as fibrous intimal hyperplasia, organising thrombi with recanalisation, focal cortical atrophy and fibrous occlusions of arteries/arterioles, thus, need to be distinguished from thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome and malignant hypertension. In spite of lack of evidence from controlled studies, hydroxychloroquine and/or antiplatelet/anticoagulant treatment can be considered in combination with immunosuppressive treatment if nephritis is present. Patients with definite APS should receive anticoagulation treatment.<xref ref-type="bibr" rid="R151">151</xref></p></sec><sec id="s3i"><title>LN and pregnancy</title><p>Pregnancy may be planned in patients with inactive lupus and UPCR <50 mg/mmol for the preceding 6 months, with GFR that should preferably be >50 ml/min. Patients with LN who are pregnant should ideally be followed by a multidisciplinary team. Stable renal disease is treated with the same drugs that are recommended as acceptable during prepregnancy counselling (hydroxychloroquine, prednisone, azathioprine). Hydroxychloroquine should be continued<xref ref-type="bibr" rid="R152">152</xref><xref ref-type="bibr" rid="R153">153</xref> or even instituted if immunosuppressive agents need to be stopped. MPA or CY should not be used in the last 3 months, and biological agents for at least 4 months—dependent upon the agent used before conception. Blood pressure should be controlled without RAAS blockers at the time of conception if possible, due to their potential teratogenic effect during the first trimester, or with switching to other agents such as nifedipine or labetalol as soon as pregnancy is confirmed.<xref ref-type="bibr" rid="R154">154</xref><xref ref-type="bibr" rid="R155">155</xref> Acetyl-salicylic acid is recommended to reduce the risk for pre-eclampsia.<xref ref-type="bibr" rid="R156">156</xref> Patients with APS are at increased risk for adverse pregnancy outcomes<xref ref-type="bibr" rid="R154">154</xref><xref ref-type="bibr" rid="R157">157</xref><xref ref-type="bibr" rid="R158">158</xref> and should be considered for anticoagulation with low-molecular-weight heparin and/or acetyl-salicylic acid depending on their history of obstetric and/or thrombotic events.<xref ref-type="bibr" rid="R151">151</xref> Warfarin must be discontinued as soon as pregnancy is confirmed. Patients with nephrotic-range proteinuria are also candidates for anticoagulation.</p><p>For monitoring, any fall in serum C3/C4 is significant given than levels usually rise during pregnancy;<xref ref-type="bibr" rid="R159">159</xref> additional investigation may be needed to rule out pre-eclampsia before diagnosing exacerbation of renal disease.<xref ref-type="bibr" rid="R160">160</xref> For active disease or pre-eclampsia, combined care with obstetricians is recommended.<xref ref-type="bibr" rid="R158">158</xref> Close surveillance for renal flare post partum is essential. In addition to acceptable medications used in stable LN, refractory cases can also be treated with calcineurin inhibitors, intravenous immunoglobulin, immunoadsorption and possibly plasma exchange, according to disease severity.<xref ref-type="bibr" rid="R156">156</xref><xref ref-type="bibr" rid="R161">161</xref></p></sec><sec id="s3j"><title>Management of paediatric LN</title><p>Children are at increased risk for renal involvement compared to adults with SLE (OR 1.5–2.4), and nephritis often is a presenting feature of paediatric SLE. Together with elevated blood pressure, fever, lymphadenopathy, skin and joint manifestations,<xref ref-type="bibr" rid="R162">162</xref> children with LN tend to have more active disease over time, receive more intensive immunosuppressive treatment and accrue more damage, often related to glucocorticoid toxicity, compared to adults.<xref ref-type="bibr" rid="R163 R164 R165 R166 R167 R168">163–168</xref> The diagnosis, management and monitoring is based on extrapolation from evidence in adults, and on the limited, non-randomised, evidence in children with LN.<xref ref-type="bibr" rid="R169 R170 R171 R172">169–172</xref> Additional considerations include the negative effect of disease activity and glucocorticoids on linear growth, and the modification of body image induced by treatment. This may represent major psychological burden especially in adolescents building their self-esteem and affecting treatment compliance.</p></sec></sec></body><back><ack><p>Support for this work was provided via grants from the EULAR Standing Committee on Clinical Affairs (ESCCA) and the ERA-EDTA.</p></ack><fn-group><fn><p><bold>Contributors:</bold> GKB performed the systematic review of the literature, organised the results and their presentation and also drafted the manuscript. JPAI is the clinical epidemiologist who supervised the analysis of the literature findings and the grading of evidence. DTB and DJ supervised the project and chaired discussions. All coauthors contributed to discussions, drafted the statements and reviewed the manuscript.</p></fn><fn><p><bold>Competing interests:</bold> None.</p></fn><fn><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertsias</surname><given-names>G</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Boletis</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics</article-title>. <source>Ann Rheum Dis</source><year>2008</year>;<volume>67</volume>:<fpage>195</fpage>–<lpage>205</lpage><pub-id pub-id-type="pmid">17504841</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dougados</surname><given-names>M</given-names></name><name><surname>Betteridge</surname><given-names>N</given-names></name><name><surname>Burmester</surname><given-names>GR</given-names></name><etal></etal></person-group><article-title>EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees</article-title>. <source>Ann Rheum Dis</source><year>2004</year>;<volume>63</volume>:<fpage>1172</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">15308532</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appenzeller</surname><given-names>S</given-names></name><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Pineau</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Isolated pyuria in systemic lupus erythematosus</article-title>. <source>Lupus</source><year>2010</year>;<volume>19</volume>:<fpage>793</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">20305045</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>P</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Ibanez</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Significance of isolated hematuria and isolated pyuria in systemic lupus erythematosus</article-title>. <source>Lupus</source><year>2001</year>;<volume>10</volume>:<fpage>418</fpage>–<lpage>23</lpage><pub-id pub-id-type="pmid">11434577</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leaker</surname><given-names>B</given-names></name><name><surname>Fairley</surname><given-names>KF</given-names></name><name><surname>Dowling</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Lupus nephritis: clinical and pathological correlation</article-title>. <source>Q J Med</source><year>1987</year>;<volume>62</volume>:<fpage>163</fpage>–<lpage>79</lpage><pub-id pub-id-type="pmid">3659257</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nossent</surname><given-names>HC</given-names></name><name><surname>Henzen-Logmans</surname><given-names>SC</given-names></name><name><surname>Vroom</surname><given-names>TM</given-names></name><etal></etal></person-group><article-title>Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients</article-title>. <source>Arthritis Rheum</source><year>1990</year>;<volume>33</volume>:<fpage>970</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">2369432</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tisseverasinghe</surname><given-names>A</given-names></name><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Greenwood</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source><year>2006</year>;<volume>54</volume>:<fpage>2211</fpage>–<lpage>19</lpage><pub-id pub-id-type="pmid">16802357</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grootscholten</surname><given-names>C</given-names></name><name><surname>Bajema</surname><given-names>IM</given-names></name><name><surname>Florquin</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis</article-title>. <source>Arthritis Rheum</source><year>2007</year>;<volume>56</volume>:<fpage>924</fpage>–<lpage>37</lpage><pub-id pub-id-type="pmid">17328070</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reich</surname><given-names>HN</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><etal></etal></person-group><article-title>Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus</article-title>. <source>Kidney Int</source><year>2011</year>;<volume>79</volume>:<fpage>914</fpage>–<lpage>20</lpage><pub-id pub-id-type="pmid">21248713</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasitanon</surname><given-names>N</given-names></name><name><surname>Fine</surname><given-names>DM</given-names></name><name><surname>Haas</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Estimating renal function in lupus nephritis: comparison of the modification of diet in renal disease and Cockcroft Gault equations</article-title>. <source>Lupus</source><year>2007</year>;<volume>16</volume>:<fpage>887</fpage>–<lpage>95</lpage><pub-id pub-id-type="pmid">17971362</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petri</surname><given-names>M</given-names></name><name><surname>Bockenstedt</surname><given-names>L</given-names></name><name><surname>Colman</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Serial assessment of glomerular filtration rate in lupus nephropathy</article-title>. <source>Kidney Int</source><year>1988</year>;<volume>34</volume>:<fpage>832</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">3210545</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esdaile</surname><given-names>JM</given-names></name><name><surname>Levinton</surname><given-names>C</given-names></name><name><surname>Federgreen</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature</article-title>. <source>Q J Med</source><year>1989</year>;<volume>72</volume>:<fpage>779</fpage>–<lpage>833</lpage><pub-id pub-id-type="pmid">2694209</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moroni</surname><given-names>G</given-names></name><name><surname>Gallelli</surname><given-names>B</given-names></name><name><surname>Quaglini</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up</article-title>. <source>Nephrol Dial Transplant</source><year>2006</year>;<volume>21</volume>:<fpage>1541</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">16455674</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faurschou</surname><given-names>M</given-names></name><name><surname>Starklint</surname><given-names>H</given-names></name><name><surname>Halberg</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure</article-title>. <source>J Rheumatol</source><year>2006</year>;<volume>33</volume>:<fpage>1563</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">16881113</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weening</surname><given-names>JJ</given-names></name><name><surname>D'Agati</surname><given-names>VD</given-names></name><name><surname>Schwartz</surname><given-names>MM</given-names></name><etal></etal></person-group><article-title>The classification of glomerulonephritis in systemic lupus erythematosus revisited</article-title>. <source>J Am Soc Nephrol</source><year>2004</year>;<volume>15</volume>:<fpage>241</fpage>–<lpage>50</lpage><pub-id pub-id-type="pmid">14747370</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furness</surname><given-names>PN</given-names></name><name><surname>Taub</surname><given-names>N</given-names></name></person-group><article-title>Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-a UK-wide study</article-title>. <source>Am J Surg Pathol</source><year>2006</year>;<volume>30</volume>:<fpage>1030</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">16861976</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grootscholten</surname><given-names>C</given-names></name><name><surname>Bajema</surname><given-names>IM</given-names></name><name><surname>Florquin</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis</article-title>. <source>Nephrol Dial Transplant</source><year>2008</year>;<volume>23</volume>:<fpage>223</fpage>–<lpage>30</lpage><pub-id pub-id-type="pmid">17981886</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Dell</surname><given-names>JR</given-names></name><name><surname>Hays</surname><given-names>RC</given-names></name><name><surname>Guggenheim</surname><given-names>SJ</given-names></name><etal></etal></person-group><article-title>Tubulointerstitial renal disease in systemic lupus erythematosus</article-title>. <source>Arch Intern Med</source><year>1985</year>;<volume>145</volume>:<fpage>1996</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">4062450</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esdaile</surname><given-names>JM</given-names></name><name><surname>Federgreen</surname><given-names>W</given-names></name><name><surname>Quintal</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Predictors of one year outcome in lupus nephritis: the importance of renal biopsy</article-title>. <source>Q J Med</source><year>1991</year>;<volume>81</volume>:<fpage>907</fpage>–<lpage>18</lpage><pub-id pub-id-type="pmid">1808631</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>HA</given-names><suffix>III</suffix></name><name><surname>Boumpas</surname><given-names>DT</given-names></name><name><surname>Vaughan</surname><given-names>EM</given-names></name><etal></etal></person-group><article-title>High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients</article-title>. <source>Nephrol Dial Transplant</source><year>1995</year>;<volume>10</volume>:<fpage>1620</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">8559480</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>GS</given-names></name><name><surname>Delahousse</surname><given-names>M</given-names></name><name><surname>Nochy</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>A new morphologic index for the evaluation of renal biopsies in lupus nephritis</article-title>. <source>Kidney Int</source><year>2000</year>;<volume>58</volume>:<fpage>1160</fpage>–<lpage>73</lpage><pub-id pub-id-type="pmid">10972679</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Kameda</surname><given-names>H</given-names></name><name><surname>Nagasawa</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis</article-title>. <source>Mod Rheumatol</source><year>2007</year>;<volume>17</volume>:<fpage>92</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">17437162</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Descombes</surname><given-names>E</given-names></name><name><surname>Droz</surname><given-names>D</given-names></name><name><surname>Drouet</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Renal vascular lesions in lupus nephritis</article-title>. <source>Medicine (Baltimore)</source><year>1997</year>;<volume>76</volume>:<fpage>355</fpage>–<lpage>68</lpage><pub-id pub-id-type="pmid">9352738</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corwin</surname><given-names>HL</given-names></name><name><surname>Schwartz</surname><given-names>MM</given-names></name><name><surname>Lewis</surname><given-names>EJ</given-names></name></person-group><article-title>The importance of sample size in the interpretation of the renal biopsy</article-title>. <source>Am J Nephrol</source><year>1988</year>;<volume>8</volume>:<fpage>85</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">3394725</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magil</surname><given-names>AB</given-names></name><name><surname>Ballon</surname><given-names>HS</given-names></name><name><surname>Chan</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>Diffuse proliferative lupus glomerulonephritis. Determination of prognostic significance of clinical, laboratory and pathologic factors</article-title>. <source>Medicine (Baltimore)</source><year>1984</year>;<volume>63</volume>:<fpage>210</fpage>–<lpage>20</lpage><pub-id pub-id-type="pmid">6377004</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nossent</surname><given-names>H</given-names></name><name><surname>Berden</surname><given-names>J</given-names></name><name><surname>Swaak</surname><given-names>T</given-names></name></person-group><article-title>Renal immunofluorescence and the prediction of renal outcome in patients with proliferative lupus nephritis</article-title>. <source>Lupus</source><year>2000</year>;<volume>9</volume>:<fpage>504</fpage>–<lpage>10</lpage><pub-id pub-id-type="pmid">11035415</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>HA</given-names><suffix>III</suffix></name><name><surname>Muenz</surname><given-names>LR</given-names></name><name><surname>Joyce</surname><given-names>KM</given-names></name><etal></etal></person-group><article-title>Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome</article-title>. <source>Kidney Int</source><year>1984</year>;<volume>25</volume>:<fpage>689</fpage>–<lpage>95</lpage><pub-id pub-id-type="pmid">6482173</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiting-O'Keefe</surname><given-names>Q</given-names></name><name><surname>Henke</surname><given-names>JE</given-names></name><name><surname>Shearn</surname><given-names>MA</given-names></name><etal></etal></person-group><article-title>The information content from renal biopsy in systemic lupus erythematosus</article-title>. <source>Ann Intern Med</source><year>1982</year>;<volume>96</volume>:<fpage>718</fpage>–<lpage>23</lpage><pub-id pub-id-type="pmid">7091935</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiting-O'Keefe</surname><given-names>Q</given-names></name><name><surname>Riccardi</surname><given-names>PJ</given-names></name><name><surname>Henke</surname><given-names>JE</given-names></name><etal></etal></person-group><article-title>Recognition of information in renal biopsies of patients with lupus nephritis</article-title>. <source>Ann Intern Med</source><year>1982</year>;<volume>96</volume>:<fpage>723</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">7091936</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faurschou</surname><given-names>M</given-names></name><name><surname>Dreyer</surname><given-names>L</given-names></name><name><surname>Kamper</surname><given-names>AL</given-names></name><etal></etal></person-group><article-title>Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis</article-title>. <source>Arthritis Care Res (Hoboken)</source><year>2010</year>;<volume>62</volume>:<fpage>873</fpage>–<lpage>80</lpage><pub-id pub-id-type="pmid">20191478</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Cheung</surname><given-names>TT</given-names></name><name><surname>Lo</surname><given-names>WH</given-names></name></person-group><article-title>Minimal mesangial lupus nephritis: a systematic review</article-title>. <source>Scand J Rheumatol</source><year>2010</year>;<volume>39</volume>:<fpage>181</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">20166847</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiramatsu</surname><given-names>N</given-names></name><name><surname>Kuroiwa</surname><given-names>T</given-names></name><name><surname>Ikeuchi</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions</article-title>. <source>Rheumatology (Oxford)</source><year>2008</year>;<volume>47</volume>:<fpage>702</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">18390590</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houssiau</surname><given-names>FA</given-names></name><name><surname>Vasconcelos</surname><given-names>C</given-names></name><name><surname>D'Cruz</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial</article-title>. <source>Arthritis Rheum</source><year>2004</year>;<volume>50</volume>:<fpage>3934</fpage>–<lpage>40</lpage><pub-id pub-id-type="pmid">15593207</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Illei</surname><given-names>GG</given-names></name><name><surname>Takada</surname><given-names>K</given-names></name><name><surname>Parkin</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies</article-title>. <source>Arthritis Rheum</source><year>2002</year>;<volume>46</volume>:<fpage>995</fpage>–<lpage>1002</lpage><pub-id pub-id-type="pmid">11953977</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Ying</surname><given-names>KY</given-names></name><name><surname>Ng</surname><given-names>WL</given-names></name><etal></etal></person-group><article-title>Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide</article-title>. <source>Am J Med</source><year>2006</year>;<volume>119</volume>:<fpage>355e25</fpage>–<lpage>33</lpage><pub-id pub-id-type="pmid">16564783</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YE</given-names></name><name><surname>Korbet</surname><given-names>SM</given-names></name><name><surname>Katz</surname><given-names>RS</given-names></name><etal></etal></person-group><article-title>Value of a complete or partial remission in severe lupus nephritis</article-title>. <source>Clin J Am Soc Nephrol</source><year>2008</year>;<volume>3</volume>:<fpage>46</fpage>–<lpage>53</lpage><pub-id pub-id-type="pmid">18003764</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Ying</surname><given-names>KY</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis</article-title>. <source>Arthritis Rheum</source><year>2004</year>;<volume>50</volume>:<fpage>2559</fpage>–<lpage>68</lpage><pub-id pub-id-type="pmid">15334470</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moroni</surname><given-names>G</given-names></name><name><surname>Quaglini</surname><given-names>S</given-names></name><name><surname>Maccario</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>‘Nephritic flares’ are predictors of bad long-term renal outcome in lupus nephritis</article-title>. <source>Kidney Int</source><year>1996</year>;<volume>50</volume>:<fpage>2047</fpage>–<lpage>53</lpage><pub-id pub-id-type="pmid">8943489</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moroni</surname><given-names>G</given-names></name><name><surname>Quaglini</surname><given-names>S</given-names></name><name><surname>Gallelli</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>The long-term outcome of 93 patients with proliferative lupus nephritis</article-title>. <source>Nephrol Dial Transplant</source><year>2007</year>;<volume>22</volume>:<fpage>2531</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">17510096</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>MM</given-names></name></person-group><article-title>Hospital experience and mortality in patients with systemic lupus erythematosus: which patients benefit most from treatment at highly experienced hospitals?</article-title><source>J Rheumatol</source><year>2002</year>;<volume>29</volume>:<fpage>1198</fpage>–<lpage>206</lpage><pub-id pub-id-type="pmid">12064835</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>HA</given-names><suffix>III</suffix></name><name><surname>Klippel</surname><given-names>JH</given-names></name><name><surname>Balow</surname><given-names>JE</given-names></name><etal></etal></person-group><article-title>Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs</article-title>. <source>N Engl J Med</source><year>1986</year>;<volume>314</volume>:<fpage>614</fpage>–<lpage>19</lpage><pub-id pub-id-type="pmid">3511372</pub-id></mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Cui</surname><given-names>TG</given-names></name><name><surname>Hou</surname><given-names>FF</given-names></name><etal></etal></person-group><article-title>Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study</article-title>. <source>Lupus</source><year>2008</year>;<volume>17</volume>:<fpage>638</fpage>–<lpage>44</lpage><pub-id pub-id-type="pmid">18625636</pub-id></mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Illei</surname><given-names>GG</given-names></name><name><surname>Austin</surname><given-names>HA</given-names></name><name><surname>Crane</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis</article-title>. <source>Ann Intern Med</source><year>2001</year>;<volume>135</volume>:<fpage>248</fpage>–<lpage>57</lpage><pub-id pub-id-type="pmid">11511139</pub-id></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houssiau</surname><given-names>FA</given-names></name><name><surname>Vasconcelos</surname><given-names>C</given-names></name><name><surname>D'Cruz</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide</article-title>. <source>Ann Rheum Dis</source><year>2010</year>;<volume>69</volume>:<fpage>61</fpage>–<lpage>4</lpage><pub-id pub-id-type="pmid">19155235</pub-id></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appel</surname><given-names>GB</given-names></name><name><surname>Contreras</surname><given-names>G</given-names></name><name><surname>Dooley</surname><given-names>MA</given-names></name><etal></etal></person-group><article-title>Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis</article-title>. <source>J Am Soc Nephrol</source><year>2009</year>;<volume>20</volume>:<fpage>1103</fpage>–<lpage>12</lpage><pub-id pub-id-type="pmid">19369404</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>TM</given-names></name><name><surname>Li</surname><given-names>FK</given-names></name><name><surname>Tang</surname><given-names>CS</given-names></name><etal></etal></person-group><article-title>Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group</article-title>. <source>N Engl J Med</source><year>2000</year>;<volume>343</volume>:<fpage>1156</fpage>–<lpage>62</lpage><pub-id pub-id-type="pmid">11036121</pub-id></mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>TM</given-names></name><name><surname>Tse</surname><given-names>KC</given-names></name><name><surname>Tang</surname><given-names>CS</given-names></name><etal></etal></person-group><article-title>Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis</article-title>. <source>J Am Soc Nephrol</source><year>2005</year>;<volume>16</volume>:<fpage>1076</fpage>–<lpage>84</lpage><pub-id pub-id-type="pmid">15728784</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginzler</surname><given-names>EM</given-names></name><name><surname>Dooley</surname><given-names>MA</given-names></name><name><surname>Aranow</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis</article-title>. <source>N Engl J Med</source><year>2005</year>;<volume>353</volume>:<fpage>2219</fpage>–<lpage>28</lpage><pub-id pub-id-type="pmid">16306519</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golshayan</surname><given-names>D</given-names></name><name><surname>Pascual</surname><given-names>M</given-names></name><name><surname>Vogt</surname><given-names>B</given-names></name></person-group><article-title>Mycophenolic acid formulations in adult renal transplantation—update on efficacy and tolerability</article-title>. <source>Ther Clin Risk Manag</source><year>2009</year>;<volume>5</volume>:<fpage>341</fpage>–<lpage>51</lpage><pub-id pub-id-type="pmid">19753127</pub-id></mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sollinger</surname><given-names>HW</given-names></name><name><surname>Sundberg</surname><given-names>AK</given-names></name><name><surname>Leverson</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients</article-title>. <source>Transplantation</source><year>2010</year>;<volume>89</volume>:<fpage>446</fpage>–<lpage>51</lpage><pub-id pub-id-type="pmid">20177347</pub-id></mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeher</surname><given-names>M</given-names></name><name><surname>Doria</surname><given-names>A</given-names></name><name><surname>Lan</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis</article-title>. <source>Lupus</source><year>2011</year>;<volume>20</volume>:<fpage>1484</fpage>–<lpage>93</lpage><pub-id pub-id-type="pmid">21976398</pub-id></mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houssiau</surname><given-names>FA</given-names></name><name><surname>Vasconcelos</surname><given-names>C</given-names></name><name><surname>D'Cruz</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide</article-title>. <source>Arthritis Rheum</source><year>2002</year>;<volume>46</volume>:<fpage>2121</fpage>–<lpage>31</lpage><pub-id pub-id-type="pmid">12209517</pub-id></mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>HA</given-names><suffix>III</suffix></name><name><surname>Illei</surname><given-names>GG</given-names></name><name><surname>Braun</surname><given-names>MJ</given-names></name><etal></etal></person-group><article-title>Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy</article-title>. <source>J Am Soc Nephrol</source><year>2009</year>;<volume>20</volume>:<fpage>901</fpage>–<lpage>11</lpage><pub-id pub-id-type="pmid">19297556</pub-id></mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radhakrishnan</surname><given-names>J</given-names></name><name><surname>Moutzouris</surname><given-names>DA</given-names></name><name><surname>Ginzler</surname><given-names>EM</given-names></name><etal></etal></person-group><article-title>Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis</article-title>. <source>Kidney Int</source><year>2010</year>;<volume>77</volume>:<fpage>152</fpage>–<lpage>60</lpage><pub-id pub-id-type="pmid">19890271</pub-id></mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isenberg</surname><given-names>D</given-names></name><name><surname>Appel</surname><given-names>GB</given-names></name><name><surname>Contreras</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study</article-title>. <source>Rheumatology (Oxford)</source><year>2010</year>;<volume>49</volume>:<fpage>128</fpage>–<lpage>40</lpage><pub-id pub-id-type="pmid">19933596</pub-id></mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginzler</surname><given-names>EM</given-names></name><name><surname>Felson</surname><given-names>DT</given-names></name><name><surname>Anthony</surname><given-names>JM</given-names></name><etal></etal></person-group><article-title>Hypertension increases the risk of renal deterioration in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source><year>1993</year>;<volume>20</volume>:<fpage>1694</fpage>–<lpage>700</lpage><pub-id pub-id-type="pmid">8295180</pub-id></mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakir</surname><given-names>AA</given-names></name><name><surname>Levy</surname><given-names>PS</given-names></name><name><surname>Dunea</surname><given-names>G</given-names></name></person-group><article-title>The prognosis of lupus nephritis in African-Americans: a retrospective analysis</article-title>. <source>Am J Kidney Dis</source><year>1994</year>;<volume>24</volume>:<fpage>159</fpage>–<lpage>71</lpage><pub-id pub-id-type="pmid">8048420</pub-id></mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boumpas</surname><given-names>DT</given-names></name><name><surname>Austin</surname><given-names>HA</given-names><suffix>III</suffix></name><name><surname>Vaughn</surname><given-names>EM</given-names></name><etal></etal></person-group><article-title>Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis</article-title>. <source>Lancet</source><year>1992</year>;<volume>340</volume>:<fpage>741</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">1356175</pub-id></mixed-citation></ref><ref id="R59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grootscholten</surname><given-names>C</given-names></name><name><surname>Ligtenberg</surname><given-names>G</given-names></name><name><surname>Hagen</surname><given-names>EC</given-names></name><etal></etal></person-group><article-title>Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial</article-title>. <source>Kidney Int</source><year>2006</year>;<volume>70</volume>:<fpage>732</fpage>–<lpage>42</lpage><pub-id pub-id-type="pmid">16820790</pub-id></mixed-citation></ref><ref id="R60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelp</surname><given-names>WD</given-names></name><name><surname>Bloodworth</surname><given-names>JM</given-names><suffix>Jr</suffix></name><name><surname>Rieselbach</surname><given-names>RE</given-names></name></person-group><article-title>Effect of azathioprine on renal histology and function in lupus nephritis</article-title>. <source>Arch Intern Med</source><year>1971</year>;<volume>128</volume>:<fpage>566</fpage>–<lpage>73</lpage><pub-id pub-id-type="pmid">5111661</pub-id></mixed-citation></ref><ref id="R61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badsha</surname><given-names>H</given-names></name><name><surname>Kong</surname><given-names>KO</given-names></name><name><surname>Lian</surname><given-names>TY</given-names></name><etal></etal></person-group><article-title>Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications</article-title>. <source>Lupus</source><year>2002</year>;<volume>11</volume>:<fpage>508</fpage>–<lpage>13</lpage><pub-id pub-id-type="pmid">12220105</pub-id></mixed-citation></ref><ref id="R62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>KO</given-names></name><name><surname>Badsha</surname><given-names>H</given-names></name><name><surname>Lian</surname><given-names>TY</given-names></name><etal></etal></person-group><article-title>Low-dose pulse methylprednisolone is an effective therapy for severe SLE flares</article-title>. <source>Lupus</source><year>2004</year>;<volume>13</volume>:<fpage>212</fpage>–<lpage>13</lpage><pub-id pub-id-type="pmid">15119552</pub-id></mixed-citation></ref><ref id="R63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraft</surname><given-names>SW</given-names></name><name><surname>Schwartz</surname><given-names>MM</given-names></name><name><surname>Korbet</surname><given-names>SM</given-names></name><etal></etal></person-group><article-title>Glomerular podocytopathy in patients with systemic lupus erythematosus</article-title>. <source>J Am Soc Nephrol</source><year>2005</year>;<volume>16</volume>:<fpage>175</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">15548564</pub-id></mixed-citation></ref><ref id="R64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>TS</given-names></name><name><surname>Schwartz</surname><given-names>MM</given-names></name><name><surname>Lewis</surname><given-names>EJ</given-names></name></person-group><article-title>Association of glomerular podocytopathy and nephrotic proteinuria in mesangial lupus nephritis</article-title>. <source>Lupus</source><year>2006</year>;<volume>15</volume>:<fpage>71</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">16539276</pub-id></mixed-citation></ref><ref id="R65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>SD</given-names></name><name><surname>Shah</surname><given-names>V</given-names></name><name><surname>Pilkington</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Renal tubular dysfunction in children with systemic lupus erythematosus</article-title>. <source>Pediatr Nephrol</source><year>2005</year>;<volume>20</volume>:<fpage>141</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">15622502</pub-id></mixed-citation></ref><ref id="R66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ter Borg</surname><given-names>EJ</given-names></name><name><surname>de Jong</surname><given-names>PE</given-names></name><name><surname>Meijer</surname><given-names>SS</given-names></name><etal></etal></person-group><article-title>Tubular dysfunction in proliferative lupus nephritis</article-title>. <source>Am J Nephrol</source><year>1991</year>;<volume>11</volume>:<fpage>16</fpage>–<lpage>22</lpage><pub-id pub-id-type="pmid">1646567</pub-id></mixed-citation></ref><ref id="R67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houssiau</surname><given-names>FA</given-names></name><name><surname>D'Cruz</surname><given-names>D</given-names></name><name><surname>Sangle</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial</article-title>. <source>Ann Rheum Dis</source><year>2010</year>;<volume>69</volume>:<fpage>2083</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">20833738</pub-id></mixed-citation></ref><ref id="R68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dooley</surname><given-names>MA</given-names></name><name><surname>Jayne</surname><given-names>D</given-names></name><name><surname>Ginzler</surname><given-names>EM</given-names></name><etal></etal></person-group><article-title>Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis</article-title>. <source>N Engl J Med</source><year>2011</year>;<volume>365</volume>:<fpage>1886</fpage>–<lpage>95</lpage><pub-id pub-id-type="pmid">22087680</pub-id></mixed-citation></ref><ref id="R69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moroni</surname><given-names>G</given-names></name><name><surname>Doria</surname><given-names>A</given-names></name><name><surname>Mosca</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years</article-title>. <source>Clin J Am Soc Nephrol</source><year>2006</year>;<volume>1</volume>:<fpage>925</fpage>–<lpage>32</lpage><pub-id pub-id-type="pmid">17699309</pub-id></mixed-citation></ref><ref id="R70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radhakrishnan</surname><given-names>J</given-names></name><name><surname>Kunis</surname><given-names>CL</given-names></name><name><surname>D'Agati</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>Cyclosporine treatment of lupus membranous nephropathy</article-title>. <source>Clin Nephrol</source><year>1994</year>;<volume>42</volume>:<fpage>147</fpage>–<lpage>54</lpage><pub-id pub-id-type="pmid">7994932</pub-id></mixed-citation></ref><ref id="R71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>MM</given-names></name><name><surname>Lan</surname><given-names>SP</given-names></name><name><surname>Bernstein</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group</article-title>. <source>Am J Kidney Dis</source><year>1993</year>;<volume>21</volume>:<fpage>374</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">8465815</pub-id></mixed-citation></ref><ref id="R72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gourley</surname><given-names>MF</given-names></name><name><surname>Austin</surname><given-names>HA</given-names><suffix>III</suffix></name><name><surname>Scott</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial</article-title>. <source>Ann Intern Med</source><year>1996</year>;<volume>125</volume>:<fpage>549</fpage>–<lpage>57</lpage><pub-id pub-id-type="pmid">8815753</pub-id></mixed-citation></ref><ref id="R73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boumpas</surname><given-names>DT</given-names></name><name><surname>Austin</surname><given-names>HA</given-names><suffix>III</suffix></name><name><surname>Vaughan</surname><given-names>EM</given-names></name><etal></etal></person-group><article-title>Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy</article-title>. <source>Ann Intern Med</source><year>1993</year>;<volume>119</volume>:<fpage>366</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">8338289</pub-id></mixed-citation></ref><ref id="R74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filler</surname><given-names>G</given-names></name><name><surname>Hansen</surname><given-names>M</given-names></name><name><surname>LeBlanc</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children</article-title>. <source>Pediatr Nephrol</source><year>2003</year>;<volume>18</volume>:<fpage>445</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">12687454</pub-id></mixed-citation></ref><ref id="R75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lertdumrongluk</surname><given-names>P</given-names></name><name><surname>Somparn</surname><given-names>P</given-names></name><name><surname>Kittanamongkolchai</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>Pharmacokinetics of mycophenolic acid in severe lupus nephritis</article-title>. <source>Kidney Int</source><year>2010</year>;<volume>78</volume>:<fpage>389</fpage>–<lpage>95</lpage><pub-id pub-id-type="pmid">20531457</pub-id></mixed-citation></ref><ref id="R76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahr</surname><given-names>N</given-names></name><name><surname>Arnaud</surname><given-names>L</given-names></name><name><surname>Marquet</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil</article-title>. <source>Arthritis Rheum</source><year>2010</year>;<volume>62</volume>:<fpage>2047</fpage>–<lpage>54</lpage><pub-id pub-id-type="pmid">20506558</pub-id></mixed-citation></ref><ref id="R77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karim</surname><given-names>MY</given-names></name><name><surname>Alba</surname><given-names>P</given-names></name><name><surname>Cuadrado</surname><given-names>MJ</given-names></name><etal></etal></person-group><article-title>Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents</article-title>. <source>Rheumatology (Oxford)</source><year>2002</year>;<volume>41</volume>:<fpage>876</fpage>–<lpage>82</lpage><pub-id pub-id-type="pmid">12154204</pub-id></mixed-citation></ref><ref id="R78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>KE</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group><article-title>Comparison of renal disease severity and outcome in patients with primary antiphospholipid syndrome, antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone</article-title>. <source>Rheumatology (Oxford)</source><year>2001</year>;<volume>40</volume>:<fpage>863</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">11511754</pub-id></mixed-citation></ref><ref id="R79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Lagares</surname><given-names>C</given-names></name><name><surname>Croca</surname><given-names>S</given-names></name><name><surname>Sangle</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts</article-title>. <source>Autoimmun Rev</source><year>2012</year>;<volume>11</volume>:<fpage>357</fpage>–<lpage>64</lpage><pub-id pub-id-type="pmid">22032879</pub-id></mixed-citation></ref><ref id="R80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos-Casals</surname><given-names>M</given-names></name><name><surname>Diaz-Lagares</surname><given-names>C</given-names></name><name><surname>Soto-Cardenas</surname><given-names>MJ</given-names></name><etal></etal></person-group><article-title>Rituximab therapy in lupus nephritis: current clinical evidence</article-title>. <source>Clin Rev Allergy Immunol</source><year>2011</year>;<volume>40</volume>:<fpage>159</fpage>–<lpage>69</lpage><pub-id pub-id-type="pmid">20419398</pub-id></mixed-citation></ref><ref id="R81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortes-Hernandez</surname><given-names>J</given-names></name><name><surname>Torres-Salido</surname><given-names>MT</given-names></name><name><surname>Medrano</surname><given-names>AS</given-names></name><etal></etal></person-group><article-title>Long-term outcomes–mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases</article-title>. <source>Nephrol Dial Transplant</source><year>2010</year>;<volume>25</volume>:<fpage>3939</fpage>–<lpage>48</lpage><pub-id pub-id-type="pmid">20538787</pub-id></mixed-citation></ref><ref id="R82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Oh</surname><given-names>KH</given-names></name><name><surname>Joo</surname><given-names>KW</given-names></name><etal></etal></person-group><article-title>Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis</article-title>. <source>Lupus</source><year>2010</year>;<volume>19</volume>:<fpage>974</fpage>–<lpage>80</lpage><pub-id pub-id-type="pmid">20581020</pub-id></mixed-citation></ref><ref id="R83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>AD</given-names></name><name><surname>Kaltreider</surname><given-names>HB</given-names></name><name><surname>Staples</surname><given-names>PJ</given-names></name><etal></etal></person-group><article-title>Cyclophosphamide in lupus nephritis: a controlled trial</article-title>. <source>Ann Intern Med</source><year>1971</year>;<volume>75</volume>:<fpage>165</fpage>–<lpage>71</lpage><pub-id pub-id-type="pmid">4104337</pub-id></mixed-citation></ref><ref id="R84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>Y</given-names></name><name><surname>Sherer</surname><given-names>Y</given-names></name><name><surname>George</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Intravenous immunoglobulin treatment of lupus nephritis</article-title>. <source>Semin Arthritis Rheum</source><year>2000</year>;<volume>29</volume>:<fpage>321</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">10805356</pub-id></mixed-citation></ref><ref id="R85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harada</surname><given-names>T</given-names></name><name><surname>Ozono</surname><given-names>Y</given-names></name><name><surname>Miyazaki</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Plasmapheresis in the treatment of rapidly progressive glomerulonephritis</article-title>. <source>Ther Apher</source><year>1997</year>;<volume>1</volume>:<fpage>366</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">10225733</pub-id></mixed-citation></ref><ref id="R86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stummvoll</surname><given-names>GH</given-names></name><name><surname>Aringer</surname><given-names>M</given-names></name><name><surname>Smolen</surname><given-names>JS</given-names></name><etal></etal></person-group><article-title>IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study</article-title>. <source>Ann Rheum Dis</source><year>2005</year>;<volume>64</volume>:<fpage>1015</fpage>–<lpage>21</lpage><pub-id pub-id-type="pmid">15640267</pub-id></mixed-citation></ref><ref id="R87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stummvoll</surname><given-names>GH</given-names></name><name><surname>Schmaldienst</surname><given-names>S</given-names></name><name><surname>Smolen</surname><given-names>JS</given-names></name><etal></etal></person-group><article-title>Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity</article-title>. <source>Nephrol Dial Transplant</source><year>2012</year>;<volume>27</volume>:<fpage>618</fpage>–<lpage>26</lpage><pub-id pub-id-type="pmid">21617196</pub-id></mixed-citation></ref><ref id="R88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tam</surname><given-names>LS</given-names></name><name><surname>Li</surname><given-names>EK</given-names></name><name><surname>Wong</surname><given-names>CK</given-names></name><etal></etal></person-group><article-title>Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial</article-title>. <source>Ann Rheum Dis</source><year>2006</year>;<volume>65</volume>:<fpage>417</fpage>–<lpage>18</lpage><pub-id pub-id-type="pmid">16474039</pub-id></mixed-citation></ref><ref id="R89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petri</surname><given-names>MA</given-names></name><name><surname>Kiani</surname><given-names>AN</given-names></name><name><surname>Post</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>Lupus Atherosclerosis Prevention Study (LAPS)</article-title>. <source>Ann Rheum Dis</source><year>2011</year>;<volume>70</volume>:<fpage>760</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">21177297</pub-id></mixed-citation></ref><ref id="R90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duran-Barragan</surname><given-names>S</given-names></name><name><surname>McGwin</surname><given-names>G</given-names><suffix>Jr</suffix></name><name><surname>Vila</surname><given-names>LM</given-names></name><etal></etal></person-group><article-title>Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus–results from LUMINA (LIX): a multiethnic US cohort</article-title>. <source>Rheumatology (Oxford)</source><year>2008</year>;<volume>47</volume>:<fpage>1093</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">18511474</pub-id></mixed-citation></ref><ref id="R91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanda</surname><given-names>H</given-names></name><name><surname>Kubo</surname><given-names>K</given-names></name><name><surname>Tateishi</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy</article-title>. <source>Lupus</source><year>2005</year>;<volume>14</volume>:<fpage>288</fpage>–<lpage>92</lpage><pub-id pub-id-type="pmid">15864915</pub-id></mixed-citation></ref><ref id="R92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tse</surname><given-names>KC</given-names></name><name><surname>Li</surname><given-names>FK</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria</article-title>. <source>Lupus</source><year>2005</year>;<volume>14</volume>:<fpage>947</fpage>–<lpage>52</lpage><pub-id pub-id-type="pmid">16425574</pub-id></mixed-citation></ref><ref id="R93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fessler</surname><given-names>BJ</given-names></name><name><surname>Alarcon</surname><given-names>GS</given-names></name><name><surname>McGwin</surname><given-names>G</given-names><suffix>Jr</suffix></name><etal></etal></person-group><article-title>Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual</article-title>. <source>Arthritis Rheum</source><year>2005</year>;<volume>52</volume>:<fpage>1473</fpage>–<lpage>80</lpage><pub-id pub-id-type="pmid">15880829</pub-id></mixed-citation></ref><ref id="R94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pons-Estel</surname><given-names>GJ</given-names></name><name><surname>Alarcon</surname><given-names>GS</given-names></name><name><surname>McGwin</surname><given-names>G</given-names><suffix>Jr</suffix></name><etal></etal></person-group><article-title>Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort</article-title>. <source>Arthritis Rheum</source><year>2009</year>;<volume>61</volume>:<fpage>830</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">19479701</pub-id></mixed-citation></ref><ref id="R95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsakonas</surname><given-names>E</given-names></name><name><surname>Joseph</surname><given-names>L</given-names></name><name><surname>Esdaile</surname><given-names>JM</given-names></name><etal></etal></person-group><article-title>A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group</article-title>. <source>Lupus</source><year>1998</year>;<volume>7</volume>:<fpage>80</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">9541091</pub-id></mixed-citation></ref><ref id="R96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marmor</surname><given-names>MF</given-names></name><name><surname>Kellner</surname><given-names>U</given-names></name><name><surname>Lai</surname><given-names>TY</given-names></name><etal></etal></person-group><article-title>Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy</article-title>. <source>Ophthalmology</source><year>2011</year>;<volume>118</volume>:<fpage>415</fpage>–<lpage>22</lpage><pub-id pub-id-type="pmid">21292109</pub-id></mixed-citation></ref><ref id="R97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Assen</surname><given-names>S</given-names></name><name><surname>Agmon-Levin</surname><given-names>N</given-names></name><name><surname>Elkayam</surname><given-names>O</given-names></name><etal></etal></person-group><article-title>EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases</article-title>. <source>Ann Rheum Dis</source><year>2011</year>;<volume>70</volume>:<fpage>414</fpage>–<lpage>22</lpage><pub-id pub-id-type="pmid">21131643</pub-id></mixed-citation></ref><ref id="R98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heijstek</surname><given-names>MW</given-names></name><name><surname>Ott de Bruin</surname><given-names>LM</given-names></name><name><surname>Bijl</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>EULAR recommendations for vaccination in paediatric patients with rheumatic diseases</article-title>. <source>Ann Rheum Dis</source><year>2011</year>;<volume>70</volume>:<fpage>1704</fpage>–<lpage>12</lpage><pub-id pub-id-type="pmid">21813547</pub-id></mixed-citation></ref><ref id="R99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosca</surname><given-names>M</given-names></name><name><surname>Tani</surname><given-names>C</given-names></name><name><surname>Aringer</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies</article-title>. <source>Ann Rheum Dis</source><year>2010</year>;<volume>69</volume>:<fpage>1269</fpage>–<lpage>74</lpage><pub-id pub-id-type="pmid">19892750</pub-id></mixed-citation></ref><ref id="R100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>R</given-names></name><name><surname>Mant</surname><given-names>C</given-names></name><name><surname>Luxton</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients</article-title>. <source>Arthritis Rheum</source><year>2007</year>;<volume>57</volume>:<fpage>619</fpage>–<lpage>25</lpage><pub-id pub-id-type="pmid">17471531</pub-id></mixed-citation></ref><ref id="R101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nyberg</surname><given-names>G</given-names></name><name><surname>Eriksson</surname><given-names>O</given-names></name><name><surname>Westberg</surname><given-names>NG</given-names></name></person-group><article-title>Increased incidence of cervical atypia in women with systemic lupus erythematosus treated with chemotherapy</article-title>. <source>Arthritis Rheum</source><year>1981</year>;<volume>24</volume>:<fpage>648</fpage>–<lpage>50</lpage><pub-id pub-id-type="pmid">7236321</pub-id></mixed-citation></ref><ref id="R102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fine</surname><given-names>DM</given-names></name><name><surname>Ziegenbein</surname><given-names>M</given-names></name><name><surname>Petri</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis</article-title>. <source>Kidney Int</source><year>2009</year>;<volume>76</volume>:<fpage>1284</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">19759526</pub-id></mixed-citation></ref><ref id="R103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>LA</given-names></name><name><surname>Birmingham</surname><given-names>DJ</given-names></name><name><surname>Shidham</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients</article-title>. <source>Nephron Clin Pract</source><year>2009</year>;<volume>113</volume>:<fpage>c177</fpage>–<lpage>82</lpage><pub-id pub-id-type="pmid">19672116</pub-id></mixed-citation></ref><ref id="R104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>YY</given-names></name><name><surname>Szeto</surname><given-names>CC</given-names></name><name><surname>Tam</surname><given-names>LS</given-names></name><etal></etal></person-group><article-title>Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis</article-title>. <source>Rheumatology (Oxford)</source><year>2007</year>;<volume>46</volume>:<fpage>649</fpage>–<lpage>52</lpage><pub-id pub-id-type="pmid">17065189</pub-id></mixed-citation></ref><ref id="R105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>LA</given-names></name><name><surname>Dillon</surname><given-names>JJ</given-names></name><name><surname>Middendorf</surname><given-names>DF</given-names></name><etal></etal></person-group><article-title>Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus</article-title>. <source>Am J Kidney Dis</source><year>1995</year>;<volume>26</volume>:<fpage>432</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">7645551</pub-id></mixed-citation></ref><ref id="R106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moroni</surname><given-names>G</given-names></name><name><surname>Radice</surname><given-names>A</given-names></name><name><surname>Giammarresi</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis</article-title>. <source>Ann Rheum Dis</source><year>2009</year>;<volume>68</volume>:<fpage>234</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">18718989</pub-id></mixed-citation></ref><ref id="R107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birmingham</surname><given-names>DJ</given-names></name><name><surname>Irshaid</surname><given-names>F</given-names></name><name><surname>Nagaraja</surname><given-names>HN</given-names></name><etal></etal></person-group><article-title>The complex nature of serum C3 and C4 as biomarkers of lupus renal flare</article-title>. <source>Lupus</source><year>2010</year>;<volume>19</volume>:<fpage>1272</fpage>–<lpage>80</lpage><pub-id pub-id-type="pmid">20605879</pub-id></mixed-citation></ref><ref id="R108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esdaile</surname><given-names>JM</given-names></name><name><surname>Abrahamowicz</surname><given-names>M</given-names></name><name><surname>Joseph</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail</article-title>. <source>Arthritis Rheum</source><year>1996</year>;<volume>39</volume>:<fpage>370</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">8607885</pub-id></mixed-citation></ref><ref id="R109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghirardello</surname><given-names>A</given-names></name><name><surname>Villalta</surname><given-names>D</given-names></name><name><surname>Morozzi</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study</article-title>. <source>Clin Exp Rheumatol</source><year>2011</year>;<volume>29</volume>:<fpage>50</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">21345292</pub-id></mixed-citation></ref><ref id="R110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaekell</surname><given-names>HP</given-names></name><name><surname>Trabandt</surname><given-names>A</given-names></name><name><surname>Grobe</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Anti-dsDNA antibody subtypes and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis</article-title>. <source>Lupus</source><year>2006</year>;<volume>15</volume>:<fpage>335</fpage>–<lpage>45</lpage><pub-id pub-id-type="pmid">16830879</pub-id></mixed-citation></ref><ref id="R111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grootscholten</surname><given-names>C</given-names></name><name><surname>Dieker</surname><given-names>JW</given-names></name><name><surname>McGrath</surname><given-names>FD</given-names></name><etal></etal></person-group><article-title>A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone</article-title>. <source>Ann Rheum Dis</source><year>2007</year>;<volume>66</volume>:<fpage>693</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">17135217</pub-id></mixed-citation></ref><ref id="R112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez-Adrianzen</surname><given-names>OA</given-names></name><name><surname>Koutouzov</surname><given-names>S</given-names></name><name><surname>Mota</surname><given-names>RM</given-names></name><etal></etal></person-group><article-title>Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies</article-title>. <source>J Rheumatol</source><year>2006</year>;<volume>33</volume>:<fpage>1538</fpage>–<lpage>44</lpage><pub-id pub-id-type="pmid">16783863</pub-id></mixed-citation></ref><ref id="R113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Ho</surname><given-names>LY</given-names></name><name><surname>Leung</surname><given-names>HW</given-names></name><etal></etal></person-group><article-title>Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus</article-title>. <source>Transl Res</source><year>2010</year>;<volume>156</volume>:<fpage>320</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">21078493</pub-id></mixed-citation></ref><ref id="R114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Vlag</surname><given-names>J</given-names></name><name><surname>Berden</surname><given-names>JH</given-names></name></person-group><article-title>Lupus nephritis: role of antinucleosome autoantibodies</article-title>. <source>Semin Nephrol</source><year>2011</year>;<volume>31</volume>:<fpage>376</fpage>–<lpage>89</lpage><pub-id pub-id-type="pmid">21839371</pub-id></mixed-citation></ref><ref id="R115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>AD</given-names></name><name><surname>Decker</surname><given-names>JL</given-names></name></person-group><article-title>A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis</article-title>. <source>Arthritis Rheum</source><year>1974</year>;<volume>17</volume>:<fpage>923</fpage>–<lpage>37</lpage><pub-id pub-id-type="pmid">4611431</pub-id></mixed-citation></ref><ref id="R116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>GS</given-names></name><name><surname>Delahousse</surname><given-names>M</given-names></name><name><surname>Nochy</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages</article-title>. <source>Kidney Int</source><year>2001</year>;<volume>59</volume>:<fpage>304</fpage>–<lpage>16</lpage><pub-id pub-id-type="pmid">11135084</pub-id></mixed-citation></ref><ref id="R117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>GS</given-names></name><name><surname>Delahousse</surname><given-names>M</given-names></name><name><surname>Nochy</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy</article-title>. <source>Kidney Int</source><year>2002</year>;<volume>61</volume>:<fpage>2176</fpage>–<lpage>86</lpage><pub-id pub-id-type="pmid">12028458</pub-id></mixed-citation></ref><ref id="R118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moroni</surname><given-names>G</given-names></name><name><surname>Pasquali</surname><given-names>S</given-names></name><name><surname>Quaglini</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Clinical and prognostic value of serial renal biopsies in lupus nephritis</article-title>. <source>Am J Kidney Dis</source><year>1999</year>;<volume>34</volume>:<fpage>530</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">10469865</pub-id></mixed-citation></ref><ref id="R119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balow</surname><given-names>JE</given-names></name><name><surname>Austin</surname><given-names>HA</given-names><suffix>III</suffix></name><name><surname>Muenz</surname><given-names>LR</given-names></name><etal></etal></person-group><article-title>Effect of treatment on the evolution of renal abnormalities in lupus nephritis</article-title>. <source>N Engl J Med</source><year>1984</year>;<volume>311</volume>:<fpage>491</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">6749206</pub-id></mixed-citation></ref><ref id="R120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correia</surname><given-names>P</given-names></name><name><surname>Cameron</surname><given-names>JS</given-names></name><name><surname>Lian</surname><given-names>JD</given-names></name><etal></etal></person-group><article-title>Why do patients with lupus nephritis die?</article-title><source>Br Med J (Clin Res Ed)</source><year>1985</year>;<volume>290</volume>:<fpage>126</fpage>–<lpage>31</lpage></mixed-citation></ref><ref id="R121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkins</surname><given-names>RM</given-names></name><name><surname>Reynolds</surname><given-names>JC</given-names></name><name><surname>Ahuja</surname><given-names>TS</given-names></name><etal></etal></person-group><article-title>Thrombotic microangiopathy in United States long-term dialysis patients</article-title>. <source>Nephrol Dial Transplant</source><year>2006</year>;<volume>21</volume>:<fpage>191</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">16204286</pub-id></mixed-citation></ref><ref id="R122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siu</surname><given-names>YP</given-names></name><name><surname>Leung</surname><given-names>KT</given-names></name><name><surname>Tong</surname><given-names>MK</given-names></name><etal></etal></person-group><article-title>Clinical outcomes of systemic lupus erythematosus patients undergoing continuous ambulatory peritoneal dialysis</article-title>. <source>Nephrol Dial Transplant</source><year>2005</year>;<volume>20</volume>:<fpage>2797</fpage>–<lpage>802</lpage><pub-id pub-id-type="pmid">16204302</pub-id></mixed-citation></ref><ref id="R123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>CH</given-names></name><name><surname>Hsu</surname><given-names>CW</given-names></name><name><surname>Yu</surname><given-names>CC</given-names></name><etal></etal></person-group><article-title>Peritoneal dialysis and hemodialysis in systemic lupus erythematosus patients: comparison of clinical outcomes</article-title>. <source>Kidney Blood Press Res</source><year>2009</year>;<volume>32</volume>:<fpage>451</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">20016213</pub-id></mixed-citation></ref><ref id="R124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nossent</surname><given-names>HC</given-names></name><name><surname>Swaak</surname><given-names>TJ</given-names></name><name><surname>Berden</surname><given-names>JH</given-names></name></person-group><article-title>Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Dutch Working Party on SLE</article-title>. <source>Am J Med</source><year>1990</year>;<volume>89</volume>:<fpage>169</fpage>–<lpage>74</lpage><pub-id pub-id-type="pmid">2382665</pub-id></mixed-citation></ref><ref id="R125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>FM</given-names></name><name><surname>Leite</surname><given-names>MA</given-names></name><name><surname>Velarde</surname><given-names>GC</given-names></name><etal></etal></person-group><article-title>Activity of systemic lupus erythematosus in end-stage renal disease patients: study in a Brazilian cohort</article-title>. <source>Am J Nephrol</source><year>2005</year>;<volume>25</volume>:<fpage>596</fpage>–<lpage>603</lpage><pub-id pub-id-type="pmid">16282677</pub-id></mixed-citation></ref><ref id="R126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodby</surname><given-names>RA</given-names></name><name><surname>Korbet</surname><given-names>SM</given-names></name><name><surname>Lewis</surname><given-names>EJ</given-names></name></person-group><article-title>Persistence of clinical and serologic activity in patients with systemic lupus erythematosus undergoing peritoneal dialysis</article-title>. <source>Am J Med</source><year>1987</year>;<volume>83</volume>:<fpage>613</fpage>–<lpage>18</lpage><pub-id pub-id-type="pmid">3499820</pub-id></mixed-citation></ref><ref id="R127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szeto</surname><given-names>CC</given-names></name><name><surname>Li</surname><given-names>PK</given-names></name><name><surname>Wong</surname><given-names>TY</given-names></name><etal></etal></person-group><article-title>Factors associated with active systemic lupus erythematosus after endstage renal disease</article-title>. <source>J Rheumatol</source><year>1998</year>;<volume>25</volume>:<fpage>1520</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">9712094</pub-id></mixed-citation></ref><ref id="R128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okano</surname><given-names>K</given-names></name><name><surname>Yumura</surname><given-names>W</given-names></name><name><surname>Nitta</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Analysis of lupus activity in end-stage renal disease treated by hemodialysis</article-title>. <source>Intern Med</source><year>2001</year>;<volume>40</volume>:<fpage>598</fpage>–<lpage>602</lpage><pub-id pub-id-type="pmid">11506299</pub-id></mixed-citation></ref><ref id="R129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sires</surname><given-names>RL</given-names></name><name><surname>Adler</surname><given-names>SG</given-names></name><name><surname>Louie</surname><given-names>JS</given-names></name><etal></etal></person-group><article-title>Poor prognosis in end-stage lupus nephritis due to nonautologous vascular access site associated septicemia and lupus flares</article-title>. <source>Am J Nephrol</source><year>1989</year>;<volume>9</volume>:<fpage>279</fpage>–<lpage>84</lpage><pub-id pub-id-type="pmid">2817017</pub-id></mixed-citation></ref><ref id="R130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rietveld</surname><given-names>A</given-names></name><name><surname>Berden</surname><given-names>JH</given-names></name></person-group><article-title>Renal replacement therapy in lupus nephritis</article-title>. <source>Nephrol Dial Transplant</source><year>2008</year>;<volume>23</volume>:<fpage>3056</fpage>–<lpage>60</lpage><pub-id pub-id-type="pmid">18662976</pub-id></mixed-citation></ref><ref id="R131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunnapradist</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>P</given-names></name><name><surname>Peng</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the Organ Procurement and Transplantation Network database</article-title>. <source>Transplantation</source><year>2006</year>;<volume>82</volume>:<fpage>612</fpage>–<lpage>18</lpage><pub-id pub-id-type="pmid">16969282</pub-id></mixed-citation></ref><ref id="R132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chelamcharla</surname><given-names>M</given-names></name><name><surname>Javaid</surname><given-names>B</given-names></name><name><surname>Baird</surname><given-names>BC</given-names></name><etal></etal></person-group><article-title>The outcome of renal transplantation among systemic lupus erythematosus patients</article-title>. <source>Nephrol Dial Transplant</source><year>2007</year>;<volume>22</volume>:<fpage>3623</fpage>–<lpage>30</lpage><pub-id pub-id-type="pmid">17640941</pub-id></mixed-citation></ref><ref id="R133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>el-Shahawy</surname><given-names>MA</given-names></name><name><surname>Aswad</surname><given-names>S</given-names></name><name><surname>Mendez</surname><given-names>RG</given-names></name><etal></etal></person-group><article-title>Renal transplantation in systemic lupus erythematosus: a single-center experience with sixty-four cases</article-title>. <source>Am J Nephrol</source><year>1995</year>;<volume>15</volume>:<fpage>123</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">7733148</pub-id></mixed-citation></ref><ref id="R134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goral</surname><given-names>S</given-names></name><name><surname>Ynares</surname><given-names>C</given-names></name><name><surname>Shappell</surname><given-names>SB</given-names></name><etal></etal></person-group><article-title>Recurrent lupus nephritis in renal transplant recipients revisited: it is not rare</article-title>. <source>Transplantation</source><year>2003</year>;<volume>75</volume>:<fpage>651</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">12640304</pub-id></mixed-citation></ref><ref id="R135"><label>135</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Signori Baracat</surname><given-names>AL</given-names></name><name><surname>Ribeiro-Alves</surname><given-names>MA</given-names></name><name><surname>Alves-Filho</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Systemic lupus erythematosus after renal transplantation: is complement a good marker for graft survival?</article-title><source>Transplant Proc</source><year>2008</year>;<volume>40</volume>:<fpage>746</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">18455005</pub-id></mixed-citation></ref><ref id="R136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contreras</surname><given-names>G</given-names></name><name><surname>Mattiazzi</surname><given-names>A</given-names></name><name><surname>Guerra</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Recurrence of lupus nephritis after kidney transplantation</article-title>. <source>J Am Soc Nephrol</source><year>2010</year>;<volume>21</volume>:<fpage>1200</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">20488956</pub-id></mixed-citation></ref><ref id="R137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>JH</given-names></name><name><surname>Amend</surname><given-names>WJ</given-names></name><name><surname>Criswell</surname><given-names>LA</given-names></name></person-group><article-title>Outcome of renal transplantation in systemic lupus erythematosus</article-title>. <source>Semin Arthritis Rheum</source><year>1997</year>;<volume>27</volume>:<fpage>17</fpage>–<lpage>26</lpage><pub-id pub-id-type="pmid">9287386</pub-id></mixed-citation></ref><ref id="R138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Chelamcharla</surname><given-names>M</given-names></name><name><surname>Baird</surname><given-names>BC</given-names></name><etal></etal></person-group><article-title>Factors affecting kidney-transplant outcome in recipients with lupus nephritis</article-title>. <source>Clin Transplant</source><year>2008</year>;<volume>22</volume>:<fpage>263</fpage>–<lpage>72</lpage><pub-id pub-id-type="pmid">18482047</pub-id></mixed-citation></ref><ref id="R139"><label>139</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Naveed</surname><given-names>A</given-names></name><name><surname>Nilubol</surname><given-names>C</given-names></name><name><surname>Melancon</surname><given-names>JK</given-names></name><etal></etal></person-group><article-title>Preemptive kidney transplantation in systemic lupus erythematosus</article-title>. <source>Transplant Proc</source><year>2011</year>;<volume>43</volume>:<fpage>3713</fpage>–<lpage>14</lpage><pub-id pub-id-type="pmid">22172832</pub-id></mixed-citation></ref><ref id="R140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moroni</surname><given-names>G</given-names></name><name><surname>Tantardini</surname><given-names>F</given-names></name><name><surname>Gallelli</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>The long-term prognosis of renal transplantation in patients with lupus nephritis</article-title>. <source>Am J Kidney Dis</source><year>2005</year>;<volume>45</volume>:<fpage>903</fpage>–<lpage>11</lpage><pub-id pub-id-type="pmid">15861356</pub-id></mixed-citation></ref><ref id="R141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>JH</given-names></name><name><surname>Amend</surname><given-names>WJ</given-names></name><name><surname>Criswell</surname><given-names>LA</given-names></name></person-group><article-title>Antiphospholipid antibody syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus</article-title>. <source>Am J Kidney Dis</source><year>1999</year>;<volume>34</volume>:<fpage>1040</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">10585313</pub-id></mixed-citation></ref><ref id="R142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaidya</surname><given-names>S</given-names></name><name><surname>Sellers</surname><given-names>R</given-names></name><name><surname>Kimball</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: a multicenter study</article-title>. <source>Transplantation</source><year>2000</year>;<volume>69</volume>:<fpage>1348</fpage>–<lpage>52</lpage><pub-id pub-id-type="pmid">10798752</pub-id></mixed-citation></ref><ref id="R143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaidya</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>CC</given-names></name><name><surname>Gugliuzza</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies</article-title>. <source>Clin Transplant</source><year>1998</year>;<volume>12</volume>:<fpage>439</fpage>–<lpage>44</lpage><pub-id pub-id-type="pmid">9787955</pub-id></mixed-citation></ref><ref id="R144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgos</surname><given-names>PI</given-names></name><name><surname>Perkins</surname><given-names>EL</given-names></name><name><surname>Pons-Estel</surname><given-names>GJ</given-names></name><etal></etal></person-group><article-title>Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution</article-title>. <source>Arthritis Rheum</source><year>2009</year>;<volume>60</volume>:<fpage>2757</fpage>–<lpage>66</lpage><pub-id pub-id-type="pmid">19714623</pub-id></mixed-citation></ref><ref id="R145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norby</surname><given-names>GE</given-names></name><name><surname>Strom</surname><given-names>EH</given-names></name><name><surname>Midtvedt</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study</article-title>. <source>Ann Rheum Dis</source><year>2010</year>;<volume>69</volume>:<fpage>1484</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">20498208</pub-id></mixed-citation></ref><ref id="R146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tektonidou</surname><given-names>MG</given-names></name><name><surname>Sotsiou</surname><given-names>F</given-names></name><name><surname>Nakopoulou</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome</article-title>. <source>Arthritis Rheum</source><year>2004</year>;<volume>50</volume>:<fpage>2569</fpage>–<lpage>79</lpage><pub-id pub-id-type="pmid">15334471</pub-id></mixed-citation></ref><ref id="R147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galindo</surname><given-names>M</given-names></name><name><surname>Gonzalo</surname><given-names>E</given-names></name><name><surname>Martinez-Vidal</surname><given-names>MP</given-names></name><etal></etal></person-group><article-title>Immunohistochemical detection of intravascular platelet microthrombi in patients with lupus nephritis and anti-phospholipid antibodies</article-title>. <source>Rheumatology (Oxford)</source><year>2009</year>;<volume>48</volume>:<fpage>1003</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">19542214</pub-id></mixed-citation></ref><ref id="R148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>YM</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name><name><surname>Frenkel</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>IgA antiphospholipid antibodies are an independent risk factor for thromboses</article-title>. <source>Lupus</source><year>2008</year>;<volume>17</volume>:<fpage>996</fpage>–<lpage>1003</lpage><pub-id pub-id-type="pmid">18852223</pub-id></mixed-citation></ref><ref id="R149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Ao</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases</article-title>. <source>Arthritis Res Ther</source><year>2009</year>;<volume>11</volume>:<fpage>R93</fpage><pub-id pub-id-type="pmid">19545416</pub-id></mixed-citation></ref><ref id="R150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheunsuchon</surname><given-names>B</given-names></name><name><surname>Rungkaew</surname><given-names>P</given-names></name><name><surname>Chawanasuntorapoj</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Prevalence and clinicopathologic findings of antiphospholipid syndrome nephropathy in Thai systemic lupus erythematosus patients who underwent renal biopsies</article-title>. <source>Nephrology (Carlton)</source><year>2007</year>;<volume>12</volume>:<fpage>474</fpage>–<lpage>80</lpage><pub-id pub-id-type="pmid">17803471</pub-id></mixed-citation></ref><ref id="R151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></name><name><surname>Cuadrado</surname><given-names>MJ</given-names></name><name><surname>Ruiz-Arruza</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies</article-title>. <source>Lupus</source><year>2011</year>;<volume>20</volume>:<fpage>206</fpage>–<lpage>18</lpage><pub-id pub-id-type="pmid">21303837</pub-id></mixed-citation></ref><ref id="R152"><label>152</label><mixed-citation publication-type="journal"><collab>The Canadian Hydroxychloroquine Study Group</collab><article-title>A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus</article-title>. <source>N Engl J Med</source><year>1991</year>;<volume>324</volume>:<fpage>150</fpage>–<lpage>4</lpage><pub-id pub-id-type="pmid">1984192</pub-id></mixed-citation></ref><ref id="R153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clowse</surname><given-names>ME</given-names></name><name><surname>Magder</surname><given-names>L</given-names></name><name><surname>Witter</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Hydroxychloroquine in lupus pregnancy</article-title>. <source>Arthritis Rheum</source><year>2006</year>;<volume>54</volume>:<fpage>3640</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">17075810</pub-id></mixed-citation></ref><ref id="R154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clowse</surname><given-names>ME</given-names></name><name><surname>Magder</surname><given-names>LS</given-names></name><name><surname>Witter</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Early risk factors for pregnancy loss in lupus</article-title>. <source>Obstet Gynecol</source><year>2006</year>;<volume>107</volume>:<fpage>293</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">16449114</pub-id></mixed-citation></ref><ref id="R155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwok</surname><given-names>LW</given-names></name><name><surname>Tam</surname><given-names>LS</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus</article-title>. <source>Lupus</source><year>2011</year>;<volume>20</volume>:<fpage>829</fpage>–<lpage>36</lpage><pub-id pub-id-type="pmid">21543513</pub-id></mixed-citation></ref><ref id="R156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imbasciati</surname><given-names>E</given-names></name><name><surname>Tincani</surname><given-names>A</given-names></name><name><surname>Gregorini</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome</article-title>. <source>Nephrol Dial Transplant</source><year>2009</year>;<volume>24</volume>:<fpage>519</fpage>–<lpage>25</lpage><pub-id pub-id-type="pmid">18565977</pub-id></mixed-citation></ref><ref id="R157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmona</surname><given-names>F</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><name><surname>Moga</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Class III–IV proliferative lupus nephritis and pregnancy: a study of 42 cases</article-title>. <source>Am J Reprod Immunol</source><year>2005</year>;<volume>53</volume>:<fpage>182</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">15760379</pub-id></mixed-citation></ref><ref id="R158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>A</given-names></name><name><surname>Oliveira</surname><given-names>GH</given-names></name><name><surname>Lahr</surname><given-names>BD</given-names></name><etal></etal></person-group><article-title>A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis</article-title>. <source>Clin J Am Soc Nephrol</source><year>2010</year>;<volume>5</volume>:<fpage>2060</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">20688887</pub-id></mixed-citation></ref><ref id="R159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buyon</surname><given-names>JP</given-names></name><name><surname>Cronstein</surname><given-names>BN</given-names></name><name><surname>Morris</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia</article-title>. <source>Am J Med</source><year>1986</year>;<volume>81</volume>:<fpage>194</fpage>–<lpage>200</lpage><pub-id pub-id-type="pmid">3740078</pub-id></mixed-citation></ref><ref id="R160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huong</surname><given-names>DL</given-names></name><name><surname>Wechsler</surname><given-names>B</given-names></name><name><surname>Vauthier-Brouzes</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre</article-title>. <source>Ann Rheum Dis</source><year>2001</year>;<volume>60</volume>:<fpage>599</fpage>–<lpage>604</lpage><pub-id pub-id-type="pmid">11350849</pub-id></mixed-citation></ref><ref id="R161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakravarty</surname><given-names>EF</given-names></name><name><surname>Colon</surname><given-names>I</given-names></name><name><surname>Langen</surname><given-names>ES</given-names></name><etal></etal></person-group><article-title>Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus</article-title>. <source>Am J Obstet Gynecol</source><year>2005</year>;<volume>192</volume>:<fpage>1897</fpage>–<lpage>904</lpage><pub-id pub-id-type="pmid">15970846</pub-id></mixed-citation></ref><ref id="R162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livingston</surname><given-names>B</given-names></name><name><surname>Bonner</surname><given-names>A</given-names></name><name><surname>Pope</surname><given-names>J</given-names></name></person-group><article-title>Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis</article-title>. <source>Lupus</source><year>2011</year>;<volume>20</volume>:<fpage>1345</fpage>–<lpage>55</lpage><pub-id pub-id-type="pmid">21951943</pub-id></mixed-citation></ref><ref id="R163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rzany</surname><given-names>B</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Whelton</surname><given-names>PK</given-names></name><etal></etal></person-group><article-title>Risk factors for hypercreatinemia in patients with systemic lupus erythematosus</article-title>. <source>Lupus</source><year>1999</year>;<volume>8</volume>:<fpage>532</fpage>–<lpage>40</lpage><pub-id pub-id-type="pmid">10483031</pub-id></mixed-citation></ref><ref id="R164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravelli</surname><given-names>A</given-names></name><name><surname>Duarte-Salazar</surname><given-names>C</given-names></name><name><surname>Buratti</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study</article-title>. <source>Arthritis Rheum</source><year>2003</year>;<volume>49</volume>:<fpage>501</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">12910556</pub-id></mixed-citation></ref><ref id="R165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>HI</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Ibanez</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source><year>2008</year>;<volume>58</volume>:<fpage>556</fpage>–<lpage>62</lpage><pub-id pub-id-type="pmid">18240232</pub-id></mixed-citation></ref><ref id="R166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiraki</surname><given-names>LT</given-names></name><name><surname>Benseler</surname><given-names>SM</given-names></name><name><surname>Tyrrell</surname><given-names>PN</given-names></name><etal></etal></person-group><article-title>Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study</article-title>. <source>J Pediatr</source><year>2008</year>;<volume>152</volume>:<fpage>550</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">18346514</pub-id></mixed-citation></ref><ref id="R167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hersh</surname><given-names>AO</given-names></name><name><surname>von Scheven</surname><given-names>E</given-names></name><name><surname>Yazdany</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source><year>2009</year>;<volume>61</volume>:<fpage>13</fpage>–<lpage>20</lpage><pub-id pub-id-type="pmid">19116979</pub-id></mixed-citation></ref><ref id="R168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taddio</surname><given-names>A</given-names></name><name><surname>Rossetto</surname><given-names>E</given-names></name><name><surname>Rose</surname><given-names>CD</given-names></name><etal></etal></person-group><article-title>Prognostic impact of atypical presentation in pediatric systemic lupus erythematosus: results from a multicenter study</article-title>. <source>J Pediatr</source><year>2010</year>;<volume>156</volume>:<fpage>972</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">20236656</pub-id></mixed-citation></ref><ref id="R169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traynor</surname><given-names>AE</given-names></name><name><surname>Schroeder</surname><given-names>J</given-names></name><name><surname>Rosa</surname><given-names>RM</given-names></name><etal></etal></person-group><article-title>Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study</article-title>. <source>Lancet</source><year>2000</year>;<volume>356</volume>:<fpage>701</fpage>–<lpage>7</lpage><pub-id pub-id-type="pmid">11085688</pub-id></mixed-citation></ref><ref id="R170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>LW</given-names></name><name><surname>Yang</surname><given-names>LY</given-names></name><name><surname>Chen</surname><given-names>WP</given-names></name><etal></etal></person-group><article-title>Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria</article-title>. <source>Br J Rheumatol</source><year>1998</year>;<volume>37</volume>:<fpage>217</fpage>–<lpage>21</lpage><pub-id pub-id-type="pmid">9569080</pub-id></mixed-citation></ref><ref id="R171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>KK</given-names></name><name><surname>Ault</surname><given-names>BH</given-names></name><name><surname>Jones</surname><given-names>DP</given-names></name><etal></etal></person-group><article-title>Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil</article-title>. <source>J Pediatr Health Care</source><year>2008</year>;<volume>22</volume>:<fpage>282</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">18761229</pub-id></mixed-citation></ref><ref id="R172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Ibanez</surname><given-names>D</given-names></name><name><surname>Ali</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide</article-title>. <source>J Rheumatol</source><year>2007</year>;<volume>34</volume>:<fpage>1491</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">17610320</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000310 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000310 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:3465859
|texte= Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:22851469" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a OpenAccessBelV2
| This area was generated with Dilib version V0.6.25. |  |